Print  |  Close

Clinical Trial Search Results

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.

All Clinical Trials

Records 1 - 762 of 762
1.
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT04996875
Protocol IDs
CGT9486-20-201
2021-001010-10
NCI-2021-09477
2.
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT05186753
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
3.
6-Hour Oxaliplatin in Preventing Nerve Damage in Patients with Advanced or Metastatic Gastrointestinal Cancer
Cancer Type
Unknown Primary
NCI ID
NCT03800693
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
4.
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Cancer Type
Brain & Spinal Cord Tumor, Hematopoietic Malignancies, Lymphoma, Neuroblastoma
NCI ID
NCT04239092
Protocol IDs
1902
NCI-2020-04584
5.
A Beta-only IL-2 ImmunoTherapY Study
Cancer Type
Bile Duct Cancer, Bladder Cancer, Cervical Cancer, Colon/Rectal Cancer, Gallbladder Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer
NCI ID
NCT05086692
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
6.
A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Cancer Type
Melanoma, Unknown Primary
NCI ID
NCT05933577
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
7.
A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma
Cancer Type
Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT05323253
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
8.
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Cancer Type
Head and Neck Cancer
NCI ID
NCT04534205
Protocol IDs
BNT113-01
NCI-2021-03177
2020-001400-41
9.
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT05675449
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
10.
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Cancer Type
Leukemia
NCI ID
NCT05006716
Protocol IDs
Treatment Sites (2)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Georgia Cancer Center at Augusta University
Augusta
11.
A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
Cancer Type
Prostate Cancer
NCI ID
NCT06516510
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
12.
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Cancer Type
Lung Cancer
NCI ID
NCT06692738
Protocol IDs
Treatment Sites (1)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
13.
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Cancer Type
Lung Cancer
NCI ID
NCT05211895
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
14.
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
Cancer Type
Liver Cancer / Hepatoblastoma
NCI ID
NCT02954094
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Atlanta
Atlanta
Piedmont Hospital - Atlanta
Atlanta
15.
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
Cancer Type
Solid Tumor
NCI ID
NCT06208878
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
16.
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT05201781
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
17.
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Cancer Type
Leukemia, Lymphoma, Non-Hodgkin Lymphoma
NCI ID
NCT06876649
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
18.
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT01351545
Protocol IDs
Treatment Sites (5)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Georgia Cancer Center at Augusta University
Augusta
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
Winship Cancer Institute of Emory University
Atlanta
19.
A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma
Cancer Type
Non-Hodgkin Lymphoma
NCI ID
NCT00078598
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
20.
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT01630733
Protocol IDs
TV1011-LC-303
2012-002447-14
21.
A Multi-site, Prospective, Observational Study in US Patients with Advanced Melanoma
Cancer Type
Melanoma
NCI ID
Protocol IDs
CA184-199
IMPULSE
BMS CA184-199
22.
A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients With Sickle Cell Disease and Other Hemoglobinopathies
Cancer Type
NCI ID
NCT01850108
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
23.
A Phase 1 Multicenter, Open-Label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Combination with Alnuctamab, Mezigdomide, or Iberdomide in Participants with Relapsed and/or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT6163898
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
24.
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT03802695
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
25.
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT06270706
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
26.
A Phase 1, Study of BMF-500 in Adults With Acute Leukemia
Cancer Type
Leukemia
NCI ID
NCT05918692
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
27.
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT05150691
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
28.
A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT04973605
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
29.
A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Cancer Type
Leukemia, Lymphoma
NCI ID
NCT03420183
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
30.
A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
Cancer Type
Lung Cancer
NCI ID
NCT06593522
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
31.
A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT05972720
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
32.
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Cancer Type
Eye Cancer, Melanoma, Unknown Primary
NCI ID
NCT06007690
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
33.
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Cancer Type
Leukemia
NCI ID
Protocol IDs
NCT01980875
34.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Head and Neck Cancer
NCI ID
NCT01772004
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
35.
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
Cancer Type
Liver Cancer / Hepatoblastoma
NCI ID
NCT06084884
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
36.
A Phase Ia/Ib Study of NMS-03597812 in Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia including patients with TP53 mutations
Cancer Type
Leukemia, Multiple Myeloma
NCI ID
NCT06549790
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
37.
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Cancer Type
NCI ID
NCT05849298
Protocol IDs
Treatment Sites (1)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
38.
A Phase II Study of CAR T-ddBCMA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
05396885
Protocol IDs
39.
A Phase II Trial of Reduced Intensity Fludarabine and Total Body Irradiation-Based Conditioning Prior to Haplo-Identical Transplantation for Patients With Hematologic Malignancies
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT05417971
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
40.
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type
Melanoma, Unknown Primary
NCI ID
NCT02339571
Protocol IDs
Treatment Sites (5)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
Winship Cancer Institute of Emory University
Atlanta
41.
A Phase III Double Blind Study On The Efficacy of Topical Aloe Vera Gel on Irradiated Breast Tissue
Cancer Type
Breast Cancer
NCI ID
Protocol IDs
42.
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT06112379
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
43.
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
Cancer Type
Colon/Rectal Cancer
NCI ID
Protocol IDs
NCT02563002
44.
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/?r Follicular Lymphoma (LEDA)
Cancer Type
Lymphoma
NCI ID
NCT05888493
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
45.
A Phase III, Single-arm, Open Label, Single Study of Topical Application of a 2 Step Radiaderm Advanced Skincare System containing LactokineTM Fluid on Radiation Dermatitis in Breast Cancer Patients Treated with Adjuvant Whole Breast Radiation Therapy
Cancer Type
Breast Cancer
NCI ID
Protocol IDs
46.
A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of Febrile Neutropenia
Cancer Type
Breast Cancer, Lung Cancer, Non-Hodgkin Lymphoma, Prostate Cancer
NCI ID
Protocol IDs
AMG 011 20170758
47.
A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN
Cancer Type
Breast Cancer, Lung Cancer, Non-Hodgkin Lymphoma, Prostate Cancer
NCI ID
Protocol IDs
AMG 011 20170758
48.
A Randomized Phase II Study of Carboplatin and Pemetrexed with or without Selpercatinib in Patients with Non-squamous RET Positive Stage IV Non-small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy, A Lung-MAP Treatment Trial
Cancer Type
Lung Cancer
NCI ID
NCT05364645
Protocol IDs
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
49.
A Randomized Study Investigating Preoperative Chemotherapy Followed by Surgery versus Surgery Alone in Patients with High Risk Retroperitoneal Sarcoma, STRASS2 Trial
Cancer Type
Sarcoma
NCI ID
NCT04031677
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
50.
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT06614192
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
51.
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Cancer Type
Eye Cancer, Melanoma, Unknown Primary
NCI ID
NCT06581406
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
52.
A Registry of Caris Target Now Test Results (Biomarker Expression Patterns) and Hematopoietic Diagnostics for Evaluation of Correlation with Clinical Outcomes for Cancer and other Patients
Cancer Type
Multiple Primaries
NCI ID
Protocol IDs
53.
A Registry of Caris Target Now Test Results (Biomarker Expression Patterns) for Evaluation of Correlation with Clinical Outcomes for Cancer
Cancer Type
Multiple Primaries
NCI ID
Protocol IDs
54.
A Registry of Cesium-131 Brachytherapy Plus Sub- lobar Resection for Early Stage Lung Cancer
Cancer Type
Lung Cancer
NCI ID
Protocol IDs
55.
A Robot (My Special Aflac Duck) for the Reduction of Medical Setting Distress in Pediatric Cancer Patients
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT04409301
Protocol IDs
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Winship Cancer Institute of Emory University
Atlanta
56.
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT05482971
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
57.
A Study Combining the Peposertib (M3814) Pill with Standard Chemotherapy in Patients with Ovarian Cancer with an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer
NCI ID
NCT04092270
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
58.
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
Cancer Type
Unknown Primary
NCI ID
NCT05171075
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
59.
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT06413498
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
60.
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Cancer Type
Multiple Myeloma
NCI ID
NCT06208150
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
61.
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)
Cancer Type
Liver Cancer / Hepatoblastoma
NCI ID
NCT05904886
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
62.
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT05459129
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
63.
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Cancer Type
Breast Cancer
NCI ID
NCT04961996
Protocol IDs
Treatment Sites (2)
Northwest Georgia Oncology Centers - Cobb Hospital (Hiram)
Hiram
Kristine Parker, RN Clinical Research Director
770-281-5131
Northwest Georgia Oncology Centers - Tanner Medical Center Villa Rica
Carrollton
Kristine Parker, RN Clinical Research Director
770-281-5101
64.
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT06497556
Protocol IDs
Treatment Sites (2)
Summit Cancer Care at the Nancy N. Lewis and J.C. Lewis Cancer & Research Pavilion
Savannah
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
65.
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT06790693
Protocol IDs
Treatment Sites (1)
Northwest Georgia Oncology Centers (NGOC) - Cobb Hospital (Marietta)
Marietta
Kristine Parker, RN Clinical Research Director
770-281-5101
66.
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT05646862
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
67.
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04712097
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
68.
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Cancer Type
Hematopoietic Malignancies, Unknown Primary
NCI ID
NCT06588478
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
69.
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT06624085
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
70.
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT04910568
Protocol IDs
GO42552
NCI-2021-07543
2021-000238-33
71.
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Cancer Type
Lung Cancer
NCI ID
NCT05142696
Protocol IDs
Treatment Sites (1)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
72.
A Study of a New Way to Treat Children and Young Adults with a Brain Tumor Called NGGCT
Cancer Type
Germ Cell Tumor, Gestational trophoblastic disease, Testicular Cancer, Unknown Primary
NCI ID
NCT04684368
Protocol IDs
ACNS2021
ACNS2021
NCI-2020-13175
73.
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Cancer Type
Bladder Cancer, Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Unknown Primary
NCI ID
NCT06120075
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
74.
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
Cancer Type
Ovarian Cancer, Solid Tumor, Unknown Primary, Uterine Cancer
NCI ID
NCT05548296
Protocol IDs
Treatment Sites (2)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Winship Cancer Institute of Emory University
Atlanta
75.
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT06369285
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
76.
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT06662786
Protocol IDs
Treatment Sites (4)
Emory Johns Creek Hospital
Johns Creek
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
77.
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Cancer Type
Lung Cancer
NCI ID
NCT06667076
Protocol IDs
Treatment Sites (2)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Winship Cancer Institute of Emory University
Atlanta
78.
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT05651932
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
79.
A Study of ASP1012 in Adults With Solid Tumors
Cancer Type
Melanoma, Stomach/ Gastric Cancer
NCI ID
NCT06171178
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
80.
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Cancer Type
Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT05365581
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
81.
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer
NCI ID
NCT06072781
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
82.
A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT06188559
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
83.
A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT03571568
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
84.
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
Cancer Type
Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
NCI ID
NCT06915246
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
85.
A Study of Combination Chemotherapy for Patients with Newly Diagnosed DAWT and Relapsed FHWT
Cancer Type
Brain Tumor, Unknown Primary, Wilms Tumor
NCI ID
NCT04322318
Protocol IDs
Treatment Sites (2)
Atrium Health Navicent
Macon
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
86.
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCI ID
NCT04104776
Protocol IDs
0209-01
NCI-2020-01007
87.
A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD
Cancer Type
Unknown Primary
NCI ID
NCT05643638
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
88.
A Study of Daratumumab
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT05438043
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
89.
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
Cancer Type
Hematopoietic Malignancies, Unknown Primary
NCI ID
NCT05250973
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
90.
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT05629585
Protocol IDs
Treatment Sites (2)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
Winship Cancer Institute of Emory University
Atlanta
91.
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT06018337
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
92.
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Cancer Type
Breast Cancer, Head and Neck Cancer, Lung Cancer, Solid Tumor, Unknown Primary
NCI ID
NCT05785741
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
93.
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Cancer Type
Bladder Cancer, Kidney Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer
NCI ID
NCT04879329
Protocol IDs
RC48G001
NCI-2022-03375
2022-500030-28
2022-500030-28-01
C5731002
KEYNOTE-D78
MK-3475-D78
RC48 G001
94.
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Cancer Type
Breast Cancer
NCI ID
NCT06492616
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
95.
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Solid Tumor
NCI ID
NCT05726864
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
96.
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT06064877
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
97.
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT06119581
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
98.
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT04764474
Protocol IDs
2020-306-GLOB1
NCI-2021-03247
99.
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT05514054
Protocol IDs
Treatment Sites (3)
Georgia Cancer Center at Augusta University
Augusta
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
100.
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT05805501
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
101.
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Cancer Type
Lung Cancer
NCI ID
NCT06077760
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
102.
A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
Cancer Type
Pancreatic Cancer, Unknown Primary
NCI ID
NCT05249101
Protocol IDs
Treatment Sites (1)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
103.
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT04133636
Protocol IDs
CR108581
2018-004124-10
68284528MMY2003
NCI-2019-07363
104.
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT06667908
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
105.
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Cancer Type
Esophogeal Cancer, Gynecologic Cancers, Lung Cancer, Ovarian Cancer, Prostate Cancer
NCI ID
NCT06238479
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
106.
A Study of NKT2152, a HIF2a Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT05119335
Protocol IDs
NKT2152-101
NCI-2021-13434
107.
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Cancer Type
Breast Cancer, Lung Cancer, Ovarian Cancer
NCI ID
NCT05877599
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
108.
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Cancer Type
Cancer-Related Syndrome, Leukemia
NCI ID
NCT05131022
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
109.
A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT06063317
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
110.
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT06136650
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
111.
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary, Uterine Cancer
NCI ID
NCT05787587
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
112.
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Cancer Type
Lymphoma, Neuroblastoma
NCI ID
NCT02332668
Protocol IDs
3475-051
NCI-2015-00528
2014-002950-38
113.
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Cancer Type
Head and Neck Cancer
NCI ID
NCT04974398
Protocol IDs
Treatment Sites (2)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Winship Cancer Institute of Emory University
Atlanta
114.
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT03093116
Protocol IDs
Treatment Sites (1)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
115.
A Study of Revumenib in Combination with Chemotherapy for Patients Diagnosed with Relapsed or Refractory Leukemia
Cancer Type
Leukemia
NCI ID
NCT05761171
Protocol IDs
AALL2121
AALL2121
NCI-2023-00503
116.
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Cancer Type
Leukemia
NCI ID
NCT04065399
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
117.
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCI ID
NCT05487170
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
118.
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
Cancer Type
Leukemia
NCI ID
NCT06226571
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
119.
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT06508658
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
120.
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Cancer Type
Cancer-Related Syndrome, Hodgkin Lymphoma, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS)
NCI ID
NCT06615050
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
121.
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
Cancer Type
Unknown Primary
NCI ID
NCT04683003
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
122.
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT04634552
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
123.
A Study of T-Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related Donor
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT02828592
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
124.
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT05490446
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
125.
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT05552222
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
126.
A Study of the Drug Selinexor with Radiation Therapy in Patients with Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor
NCI ID
NCT05099003
Protocol IDs
ACNS1821
ACNS1821
NCI-2021-11337
127.
A Study of the Drugs Selumetinib versus Carboplatin/Vincristine in Patients with Neurofibromatosis and Low-Grade Glioma
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT03871257
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
128.
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients with Low-Grade Glioma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor
NCI ID
NCT04166409
Protocol IDs
ACNS1833
ACNS1833
NCI-2019-07600
129.
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
Cancer Type
Head and Neck Cancer
NCI ID
NCT06457503
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
130.
A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT05473910
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
131.
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Melanoma
NCI ID
NCT02817633
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
132.
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT05253651
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
133.
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Cancer Type
Cervical Cancer
NCI ID
NCT05032040
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
134.
A Study of XMT-1660 in Participants With Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT05377996
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
135.
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT05100862
Protocol IDs
BGB-3111-308
NCI-2023-09690
2022-502548-12-00
CTR20232545
136.
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Cancer Type
Lung Cancer
NCI ID
NCT05967689
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
137.
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
Cancer Type
Unknown Primary, Uterine Cancer
NCI ID
NCT04814108
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
138.
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients with Recurrent Glioma with Elevated Mutational Burden
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT04145115
Protocol IDs
A071702
A071702
NCI-2019-07242
139.
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Cancer Type
Lung Cancer
NCI ID
NCT06568939
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
140.
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT06312137
Protocol IDs
Treatment Sites (3)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
141.
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT05907304
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
142.
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Cancer Type
Brain & Spinal Cord Tumor, Melanoma, Solid Tumor, Thyroid Cancer
NCI ID
NCT05503797
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
143.
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
Cancer Type
Stomach/ Gastric Cancer
NCI ID
NCT04931654
Protocol IDs
D9570C00001
NCI-2022-01956
152970
2021-000036-57
144.
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
Cancer Type
Germ Cell Tumor
NCI ID
NCT04192344
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
145.
A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT04546399
Protocol IDs
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
146.
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients with High Risk Rhabdomyosarcoma
Cancer Type
Sarcoma, Unknown Primary
NCI ID
NCT04994132
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
147.
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT05827016
Protocol IDs
Treatment Sites (3)
Georgia Cancer Center at Augusta University
Augusta
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
Winship Cancer Institute of Emory University
Atlanta
148.
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Cancer Type
Cervical Cancer, Unknown Primary
NCI ID
NCT06459180
Protocol IDs
Treatment Sites (2)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
149.
A Study to Compare Standard Chemotherapy to Therapy with CPX-351 and/or Gilteritinib for Patients with Newly Diagnosed AML with or without FLT3 Mutations
Cancer Type
Leukemia
NCI ID
NCT04293562
Protocol IDs
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
150.
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Cancer Type
Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary
NCI ID
NCT05675410
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
151.
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)
Cancer Type
Multiple Myeloma
NCI ID
NCT06615479
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
152.
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Cancer Type
Lung Cancer
NCI ID
NCT06646276
Protocol IDs
Treatment Sites (1)
Northwest Georgia Oncology Centers (NGOC) - Cobb Hospital (Marietta)
Marietta
Kristine Parker, RN Clinical Research Director
770-281-5101
153.
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT06045806
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
154.
A Study to Compare Treatment with the Drug Selumetinib Alone versus Selumetinib and Vinblastine in Patients with Recurrent or Progressive Low-Grade Glioma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary
NCI ID
NCT04576117
Protocol IDs
ACNS1931
ACNS1931
NCI-2020-07549
155.
A Study to Compare Two Surgical Procedures in Individuals with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Cancer Type
Ovarian Cancer
NCI ID
NCT04251052
Protocol IDs
Treatment Sites (5)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Summit Cancer Care at the Nancy N. Lewis and J.C. Lewis Cancer & Research Pavilion
Savannah
156.
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Cancer Type
Non-Hodgkin Lymphoma
NCI ID
NCT05283720
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
157.
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT05451810
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
158.
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT06065748
Protocol IDs
Treatment Sites (2)
Georgia Cancer Center for Excellence at Grady
Atlanta
Scott Edelman
404-489-9000
Winship Cancer Institute of Emory University
Atlanta
159.
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT05552976
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
160.
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Cancer Type
Multiple Myeloma
NCI ID
NCT05519085
Protocol IDs
Treatment Sites (1)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
161.
A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...
Cancer Type
Leukemia
NCI ID
NCT05621291
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
162.
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
Cancer Type
Esophogeal Cancer, Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT06356311
Protocol IDs
2870-015
NCI-2024-06314
2023-505423-31
2023-505423-31-00
jRCT2031240133
MK-2870-015
U1111-1291-7109
163.
A Study to Evaluate Tabelecleucel in Participants with Epstein-barr Virus-associated Diseases
Cancer Type
Sarcoma
NCI ID
NCT04554914
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
164.
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-Line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-Treatment Period.
Cancer Type
Leukemia
NCI ID
NCT06524375
Protocol IDs
Treatment Sites (1)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
165.
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
Cancer Type
Lung Cancer
NCI ID
NCT06010329
Protocol IDs
Treatment Sites (1)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
166.
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04970901
Protocol IDs
Treatment Sites (2)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
167.
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT06121843
Protocol IDs
Treatment Sites (2)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
Winship Cancer Institute of Emory University
Atlanta
168.
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT05581004
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
169.
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Cancer Type
Solid Tumor
NCI ID
NCT06004245
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
170.
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Cancer Type
Multiple Myeloma
NCI ID
NCT06271252
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
171.
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Cancer Type
Gynecologic Cancers, Lung Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Solid Tumor
NCI ID
NCT04300556
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
172.
A Study to Examine Computerized Training to Improve Concentration, Learning New Things, and Remembering in Stage I-III Breast Cancer Survivors
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT05896189
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
173.
A Study to Examine How Often (Every 5 Years or 10 Years) a Colonoscopy Should be Done in Participants Who Had One or Two Small Growths of Tissue Removed from Their Colon
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT05080673
Protocol IDs
NRG-CC005
NRG-CC005
NRG-CC005
NCI-2020-00733
174.
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Cancer Type
Multiple Myeloma
NCI ID
NCT05137054
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
175.
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
Cancer Type
Leukemia
NCI ID
NCT06637501
Protocol IDs
Treatment Sites (1)
Northwest Georgia Oncology Centers (NGOC) - Cobb Hospital (Marietta)
Marietta
Kristine Parker, RN Clinical Research Director
770-281-5101
176.
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT06417814
Protocol IDs
Treatment Sites (1)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
177.
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT06008093
Protocol IDs
Treatment Sites (1)
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
178.
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML
Cancer Type
Leukemia
NCI ID
NCT05735184
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
179.
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT04946864
Protocol IDs
APG2575XU103
NCI-2021-11630
180.
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Cancer Type
Multiple Myeloma
NCI ID
NCT06215118
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
181.
A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Cancer Type
Lung Cancer
NCI ID
NCT06452277
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
182.
A Study to Learn More About the Health of Persons with Down Syndrome After Treatment for Acute Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT05702645
Protocol IDs
ALTE22C1
ALTE22C1
ALTE22C1
NCI-2022-09410
183.
A Study to See if Memantine Protects the Brain during Radiation Therapy Treatment for Primary Central Nervous System Tumors
Cancer Type
Unknown Primary
NCI ID
NCT04939597
Protocol IDs
ACCL2031
ACCL2031
COG-ACCL2031
NCI-2020-07502
184.
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
Cancer Type
Unknown Primary
NCI ID
NCT06143891
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
185.
A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
Cancer Type
Lung Cancer
NCI ID
NCT04429087
Protocol IDs
1438-0001
NCI-2021-01392
2019-000729-31
186.
A Study with Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Cancer Type
Hematopoietic Malignancies, Unknown Primary
NCI ID
NCT05828069
Protocol IDs
ANHL2121
ANHL2121
NCI-2022-06282
NCT05287295
187.
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
Cancer Type
Cervical Cancer
NCI ID
NCT04831580
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
188.
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT03970447
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
189.
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
Cancer Type
Bile Duct Cancer, Stomach/ Gastric Cancer
NCI ID
NCT04396821
Protocol IDs
TST001-1001
NCI-2020-05881
190.
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Cancer Type
Melanoma
NCI ID
NCT06190951
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
191.
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT06091254
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
192.
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Cancer Type
Liver Cancer / Hepatoblastoma
NCI ID
NCT06040099
Protocol IDs
Treatment Sites (2)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
193.
A Web-based Dyadic Intervention to Manage Psychoneurological Symptoms for Patients with Colorectal Cancer and Their Caregivers
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT05663203
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
194.
Abatacept Extended Dosing Compared to Abatacept Short-Term Dosing for the Prevention of Graft versus Host Disease, ABA3 Study
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT04380740
Protocol IDs
20-227
NCI-2022-03010
195.
Abemaciclib and Radiation Therapy in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Recurrent or Refractory Solid Tumors, or Malignant Brain Tumors
Cancer Type
Brain & Spinal Cord Tumor, Neuroblastoma, Sarcoma
NCI ID
NCT02644460
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
196.
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04883437
Protocol IDs
WINSHIP5186-20
NCI-2021-00894
STUDY00002247
197.
Accelerated or Standard BEP Chemotherapy in Treating Patients with Intermediate or Poor-Risk Metastatic Germ Cell Tumors
Cancer Type
Germ Cell Tumor, Testicular Cancer
NCI ID
NCT02582697
Protocol IDs
Treatment Sites (3)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Atrium Health Navicent
Macon
Georgia Cancer Center at Augusta University
Augusta
198.
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT05653271
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
199.
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors
Cancer Type
Germ Cell Tumor, Testicular Cancer
NCI ID
NCT03067181
Protocol IDs
Treatment Sites (2)
Atrium Health Navicent
Macon
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
200.
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Cancer Type
Head and Neck Cancer
NCI ID
NCT05814666
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
201.
ADCT-602 in Treating Patients with Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT03698552
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
202.
Adding an Immunotherapy Drug, MEDI4736 (durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT06058377
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
203.
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Cancer Type
Lung Cancer
NCI ID
NCT06616584
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
204.
Additional Support Program via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
Cancer Type
Breast Cancer
NCI ID
NCT04379570
Protocol IDs
Treatment Sites (1)
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
205.
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Cancer Type
Solid Tumor
NCI ID
NCT03391778
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
206.
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT04849910
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
207.
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
Cancer Type
Leukemia
NCI ID
NCT05487651
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
208.
AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Cancer Type
Lung Cancer
NCI ID
NCT06333951
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
209.
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT05952557
Protocol IDs
Treatment Sites (2)
Northwest Georgia Oncology Centers (NGOC) - Cobb Hospital (Marietta)
Marietta
Kristine Parker, RN Clinical Research Director
770-281-5101
Winship Cancer Institute of Emory University
Atlanta
210.
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
Cancer Type
Melanoma
NCI ID
NCT03897881
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
211.
An Internet-Based Application for Improving Adherence to Endocrine Therapy among Patients with Early Stage Hormone Receptor Positive, HER2-Negative Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT05488145
Protocol IDs
Treatment Sites (4)
Emory Johns Creek Hospital
Johns Creek
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
212.
An Internet-based Program to Help Cancer Survivors Manage Pain (IMPACTS)
Cancer Type
Cancer Control
NCI ID
NCT04462302
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
213.
An Internet-Based Program to Help Cancer Survivors Manage Pain, IMPACTS Study
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT04462302
Protocol IDs
WF-1901
WF-1901
WF-1901
NCI-2020-02315
214.
An Investigational Imaging Technique (Quantitative Oblique Back Illumination Microscopy) during Brain Surgery for the Detection of Brain Tumors and Brain Tumor Margins
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor
NCI ID
NCT05513859
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
215.
An Investigational Scan (18F-rhPSMA 7.3 PET/CT) with and without Furosemide for the Reduction of Bladder Activity in Patients with Biochemically Recurrent Prostate Cancer
Cancer Type
Prostate Cancer
NCI ID
NCT05779943
Protocol IDs
Treatment Sites (4)
Emory Johns Creek Hospital
Johns Creek
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
216.
An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT05364086
Protocol IDs
Treatment Sites (21)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
404-303-3355
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Atlanta Head and Neck Associates
Atlanta
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Decatur
Decatur
404-303-3355
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
John B Amos Cancer Center
Columbus
Courtney Dean Alexander
706-780-6201
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
217.
An Observational Research Study to Uncover Subtypes of Cancer Cachexia, LOTUS-CC Study
Cancer Type
Colon/Rectal Cancer, Lung Cancer
NCI ID
NCT06073431
Protocol IDs
Treatment Sites (3)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
218.
An Open Label, Expanded Access Protocol Using 131I-metaiodobenzylguanidine (131I-MIBG)Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Cancer Type
Adrenal Cancer, Neuroblastoma
NCI ID
NCT01590680
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
219.
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT05011058
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
220.
AOA-PRT-0001: Collection and Banking of Blood Samples for the Study of Female Gynecological Diseases
Cancer Type
Gynecologic Cancers, Ovarian Cancer
NCI ID
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
221.
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Cancer Type
Pancreatic Cancer
NCI ID
NCT04858334
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
222.
Arginine and Whole Brain Radiation Therapy for the Treatment of Patients with Brain Metastases
Cancer Type
Brain & Spinal Cord Tumor, Solid Tumor, Unknown Primary
NCI ID
NCT06328686
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
223.
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT04662580
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
224.
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Cancer Type
Breast Cancer
NCI ID
NCT04829604
Protocol IDs
Treatment Sites (2)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
Winship Cancer Institute of Emory University
Atlanta
225.
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
Cancer Type
Leukemia
NCI ID
NCT05143840
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
226.
Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
Cancer Type
Leukemia
NCI ID
NCT05384587
Protocol IDs
Treatment Sites (2)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Winship Cancer Institute of Emory University
Atlanta
227.
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed At Least Two Lines of Therapy
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03769506
Protocol IDs
ASP-1929-301
NCI-2019-01324
228.
Atezolizumab for the Treatment of Patients with Resectable, Human Papillomavirus Related Oropharyngeal Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Unknown Primary
NCI ID
NCT06254911
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
229.
Atezolizumab in Combination with Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma (AflacST2301)
Cancer Type
Bone Tumor
NCI ID
NCT06492954
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
230.
Augusta University NH-BRAG-ONC: The Medical Center, Navicent Health Tumor Tissue and Serum Repository
Cancer Type
NCI ID
Protocol IDs
Treatment Sites (1)
Atrium Health Navicent
Macon
231.
Autologous CD19/CD22 Chimeric Antigen Receptor T-cells in Treating Patients with Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT03233854
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
232.
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT04614103
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
233.
AWAKE Mobile Application and Coaching Phone Calls in Improving Health-Promoting Behaviors in Adolescent Cancer Survivors and Their Guardians
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT03564587
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
234.
AYA-RISE for the Improvement of Cancer Risk Communication and Decision-Making in Adolescents and Young Adults with Cancer Risk Syndromes
Cancer Type
Cancer-Related Syndrome
NCI ID
NCT04323774
Protocol IDs
20-003
NCI-2020-03811
235.
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT06106945
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
236.
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Cancer Type
Esophogeal Cancer, Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT06346392
Protocol IDs
Treatment Sites (4)
Northwest Georgia Oncology Centers - Cobb Hospital (Hiram)
Hiram
Kristine Parker, RN Clinical Research Director
770-281-5131
Northwest Georgia Oncology Centers - Tanner Medical Center Villa Rica
Carrollton
Kristine Parker, RN Clinical Research Director
770-281-5101
Northwest Georgia Oncology Centers (NGOC) - Cobb Hospital (Marietta)
Marietta
Kristine Parker, RN Clinical Research Director
770-281-5101
Winship Cancer Institute of Emory University
Atlanta
237.
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
Cancer Type
Lung Cancer
NCI ID
NCT04886804
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
238.
Behavioral Parenting Skills As A Novel Target for Improving Pediatric Medication Adherence
Cancer Type
Leukemia
NCI ID
NCT05587582
Protocol IDs
I 1832021
NCI-2021-09311
239.
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT05208307
Protocol IDs
Winship5382-21
NCI-2021-08385
STUDY00003092
240.
Biomarker-Driven Radiation Therapy Dose Reduction after Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCI ID
NCT05387915
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
241.
Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)
Cancer Type
Lung Cancer
NCI ID
NCT03851445
Protocol IDs
Treatment Sites (17)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
404-303-3355
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Center at Augusta University
Augusta
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Decatur
Decatur
404-303-3355
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
242.
Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor, Unknown Primary
NCI ID
NCT04955808
Protocol IDs
DCP-002
DCP-002
DCP-002
NCI-2017-01572
243.
Blinatumomab in Treating Patients with Pre B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Stem Cell Transplant
Cancer Type
Non-Hodgkin Lymphoma
NCI ID
NCT03114865
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
244.
Blue Light Cystoscopy With Cysview® Registry
Cancer Type
Bladder Cancer
NCI ID
NCT02660645
Protocol IDs
BLCCR-001
NCI-2018-00299
245.
BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy
Cancer Type
Liver Cancer / Hepatoblastoma
NCI ID
NCT05250895
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
246.
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated with Brentuximab Vedotin or Checkpoint Inhibitors
Cancer Type
Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary
NCI ID
NCT05039073
Protocol IDs
Treatment Sites (2)
Emory Saint Joseph's Hospital
Atlanta
Winship Cancer Institute of Emory University
Atlanta
247.
Brentuximab Vedotin and Nivolumab with or without Ipilimumab in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary
NCI ID
NCT01896999
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
248.
Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
Cancer Type
Solid Tumor
NCI ID
NCT03996265
Protocol IDs
Treatment Sites (3)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
249.
Cabozantinib and Isotretinoin in Treating Children with Relapsed or Refractory Solid Tumors
Cancer Type
Brain & Spinal Cord Tumor, Solid Tumor, Unknown Primary
NCI ID
NCT03611595
Protocol IDs
171971
NCI-2018-02497
250.
Cabozantinib in Combination with Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Cancer Type
Bladder Cancer, Unknown Primary
NCI ID
NCT04878029
Protocol IDs
WINSHIP5259-21
NCI-2021-01365
STUDY00002329
251.
Cabozantinib or Sunitinib Malate in Treating Participants with Metastatic Variant Histology Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT03541902
Protocol IDs
2017-0725
NCI-2018-01041
252.
Canakinumab and Darbepoetin Alfa for the Treatment of Lower-Risk Myelodysplastic Syndromes in Patients Who Have Failed Erythropoietin Stimulating Agents
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT04798339
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
253.
CAR T-cell Therapy in Patients With Renal Dysfunction ( Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy in Patients With Moderate-Severe Renal Dysfunction)
Cancer Type
Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma
NCI ID
NCT05909059
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
254.
Caris Biorepository Research Protocol
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT01499394
Protocol IDs
Treatment Sites (2)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Southeastern Urology Associates - Macon
Macon
Ginger Safford, RN
478-742-0932
255.
CAR-T Long Term Follow Up (LTFU) Study
Cancer Type
NCI ID
NCT02445222
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
256.
Castle NH-CBI_2019_SLNBprosp_001:DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)
Cancer Type
Melanoma
NCI ID
Protocol IDs
Treatment Sites (1)
Atrium Health Navicent
Macon
257.
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, including CNS Tumors and Lymphoma
Cancer Type
Lymphoma, Sarcoma
NCI ID
NCT04870944
Protocol IDs
PEPN2111
PEPN2111
NCI-2021-03150
258.
Cemiplimab before and after Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer
Cancer Type
Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT04428671
Protocol IDs
Winship4851-19
NCI-2019-07373
IRB00115160
259.
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Cancer Type
Bladder Cancer, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Prostate Cancer , Sarcoma, Solid Tumor, Stomach/ Gastric Cancer, Thyroid Cancer
NCI ID
NCT05366881
Protocol IDs
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
260.
Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell Transplantation
Cancer Type
Lymphoma, Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT06328699
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
261.
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Cancer Type
Bone Tumor
NCI ID
NCT05106296
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
262.
Chemotherapy Combined with Immunotherapy versus Immunotherapy alone for Older Adults with Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT06096844
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
263.
Chemotherapy for the Treatment of Patients with Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Cancer Type
Sarcoma, Unknown Primary
NCI ID
NCT05304585
Protocol IDs
ARST2032
ARST2032
NCI-2022-01012
264.
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
Cancer Type
Lung Cancer
NCI ID
NCT05271292
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
265.
Childhood Cancer Predisposition Study
Cancer Type
Cancer-Related Syndrome
NCI ID
NCT04511806
Protocol IDs
CHOA4972-20
NCI-2020-01621
STUDY00000109
266.
Childhood Cancer Survivor Study
Cancer Type
Brain & Spinal Cord Tumor, Hodgkin Lymphoma, Leukemia, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Solid Tumor
NCI ID
NCT01120353
Protocol IDs
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
267.
Cholecalciferol in Improving Survival in Patients with Newly Diagnosed Cancer with Vitamin D Insufficiency
Cancer Type
Leukemia, Lymphoma
NCI ID
NCT01787409
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
268.
CIBMTR Research Database
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT01166009
Protocol IDs
Treatment Sites (2)
Georgia Cancer Center at Augusta University
Augusta
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
269.
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults with Hepatoblastoma or Liver Cancer After Surgery
Cancer Type
Brain Tumor, Liver Cancer / Hepatoblastoma
NCI ID
NCT03533582
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
270.
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT02781883
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
271.
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
Cancer Type
Unknown Primary
NCI ID
NCT06517641
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
272.
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Cancer Type
Leukemia
NCI ID
NCT03850574
Protocol IDs
HM-FLTI-101
NCI-2019-06837
273.
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Cancer Type
Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT05143996
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
274.
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Cancer Type
Cancer-Related Syndrome, Hodgkin Lymphoma, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma
NCI ID
NCT06059391
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
275.
Collecting Blood Samples from Patients with and without Cancer to Evaluate Tests for Early Cancer Detection
Cancer Type
Breast Cancer, Head and Neck Cancer, Hematopoietic Malignancies, Kidney Cancer, Leukemia, Melanoma, Sarcoma, Solid Tumor, Thyroid Cancer, Unknown Primary
NCI ID
NCT05334069
Protocol IDs
Treatment Sites (1)
Low Country Cancer Care Associates, PC
Savannah
276.
Collection and Storage of Tissue and Blood Samples from Patients with Cancer
Cancer Type
Solid Tumor
NCI ID
NCT02474160
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
277.
Collection of Research Data and Samples from Patients Treated with Immunotherapy to Study Its Side Effects
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT04242095
Protocol IDs
A151804
A151804
NCI-2019-07113
278.
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients with Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT02997228
Protocol IDs
Treatment Sites (4)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
Southern Regional Medical Center
Riverdale
Stephen Cohen, MD
770-997-1975
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
279.
Combining Radiation Therapy with Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT05721755
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
280.
Communication Issues in Patient and Provider Discussions of Immunotherapy
Cancer Type
Solid Tumor
NCI ID
NCT05873608
Protocol IDs
Treatment Sites (2)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Winship Cancer Institute of Emory University
Atlanta
281.
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined with Radiation for Patients with Advanced Head and Neck Cancer
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT05050162
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
282.
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer that has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Cancer Type
Lung Cancer
NCI ID
NCT05642572
Protocol IDs
Treatment Sites (3)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
283.
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy, The Ice Compress Trial
Cancer Type
Solid Tumor
NCI ID
NCT05642611
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
284.
Comparing Inotuzumab Combined with Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults with CD22+ B-cell Acute Lymphoblastic Leukemia
Cancer Type
Leukemia
NCI ID
NCT05303792
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
285.
Comparing New Treatments for People with Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Cancer Type
Leukemia
NCI ID
NCT06672146
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
286.
Comparing Oral Drug Dosing Strategies in Older Patients with Metastatic Breast Cancer to Maximize Tolerance and Reduce Discontinuation: the CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Cancer Type
Breast Cancer
NCI ID
NCT06377852
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
287.
Comparing Overall Survival using Markers to Direct Cancer Monitoring versus Usual Monitoring in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT03723928
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
288.
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Cancer Type
Esophogeal Cancer, Unknown Primary
NCI ID
NCT03801876
Protocol IDs
NRG-GI006
NRG-GI006
NCI-2018-03378
289.
Comparing Sentinel Lymph Node (SLN) Biopsy with Standard Neck Dissection for Patients with Early-Stage Oral Cavity Cancer
Cancer Type
Head and Neck Cancer
NCI ID
NCT04333537
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
290.
Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment
Cancer Type
Solid Tumor
NCI ID
NCT06279013
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
291.
Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplastic Syndrome-Related Changes
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT04802161
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
292.
Comparing the Addition of Radiation either before or after Surgery for Patients with Brain Metastases
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCI ID
NCT05438212
Protocol IDs
Treatment Sites (1)
Piedmont Columbus Regional
Columbus
293.
Comparing the Outcome of Standard Systemic Therapy Only versus Standard Systemic Therapy with Either Surgery or Radiation Therapy, for Patients with Advanced Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT03678025
Protocol IDs
Treatment Sites (2)
Emory Saint Joseph's Hospital
Atlanta
Winship Cancer Institute of Emory University
Atlanta
294.
Comparing Two Methods to Follow Patients with Pancreatic Cysts
Cancer Type
Unknown Primary
NCI ID
NCT04239573
Protocol IDs
EA2185
EA2185
ECOG-ACRIN-EA2185
NCI-2019-04790
295.
Comparison of Chemotherapy before and after Surgery versus after Surgery Alone for the Treatment of Gallbladder Cancer, OPT-IN Trial
Cancer Type
Gallbladder Cancer, Unknown Primary
NCI ID
NCT04559139
Protocol IDs
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
296.
Comparison of Surgery to Stereotactic Body Radiation Therapy (SBRT) in Patients With Stage I Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT05183932
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
297.
Connect® MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Cancer Type
Leukemia
NCI ID
NCT01688011
Protocol IDs
298.
Connect® Myeloid Disease Registry
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT01688011
Protocol IDs
Treatment Sites (4)
Georgia Cancer Center at Augusta University
Augusta
Northwest Georgia Oncology Centers - Cobb Hospital (Hiram)
Hiram
Kristine Parker, RN Clinical Research Director
770-281-5131
Northwest Georgia Oncology Centers - Tanner Medical Center Villa Rica
Carrollton
Kristine Parker, RN Clinical Research Director
770-281-5101
Piedmont Columbus Regional
Columbus
299.
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Cancer Type
Non-Hodgkin Lymphoma
NCI ID
NCT04637763
Protocol IDs
Treatment Sites (2)
Georgia Cancer Center at Augusta University
Augusta
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
300.
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Cancer Type
Leukemia
NCI ID
NCT06128044
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
301.
Curcumin in Treating HIV Infected and Uninfected Women with High Grade Cervical Squamous Intraepithelial Neoplasia
Cancer Type
Cervical Cancer
NCI ID
NCT02944578
Protocol IDs
Treatment Sites (3)
Emory University Hospital - Atlanta
Atlanta
Georgia Cancer Center for Excellence at Grady
Atlanta
Scott Edelman
404-489-9000
Grady Memorial Hospital
Atlanta
302.
CX-4945 in Treating Patients with Recurrent SHH Medulloblastoma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary
NCI ID
NCT03904862
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
303.
Dabrafenib Combined with Trametinib after Radiation Therapy in Treating Patients with Newly-Diagnosed High-Grade Glioma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor
NCI ID
NCT03919071
Protocol IDs
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
304.
Dabrafenib, Trametinib, and IMRT in Treating Patients with BRAF Mutated Anaplastic or Poorly Differentiated Thyroid Cancer
Cancer Type
Thyroid Cancer
NCI ID
NCT03975231
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
305.
DALY II USA/ MB-CART2019.1 for DLBCL
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04792489
Protocol IDs
Treatment Sites (2)
Georgia Cancer Center at Augusta University
Augusta
Winship Cancer Institute of Emory University
Atlanta
306.
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma with Kidney Failure
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT04352205
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
307.
DAREON??-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT06077500
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
308.
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
Cancer Type
Neuroendocrine Tumor, Unknown Primary
NCI ID
NCT06132113
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
309.
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT05555732
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
310.
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT06075953
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
311.
Decision Support Training for Family Caregivers of Patients with Advanced Cancer, CASCADE Factorial Study
Cancer Type
Breast Cancer, Head and Neck Cancer, Lung Cancer, Melanoma
NCI ID
NCT04803604
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
312.
DECOY20 Study in Patients With Advanced Solid Tumors
Cancer Type
Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer
NCI ID
NCT05651022
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
313.
De-intensified Radiation Therapy with Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients with Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCI ID
NCT03952585
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Grady Memorial Hospital
Atlanta
314.
Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT06216574
Protocol IDs
Treatment Sites (1)
Atrium Health Navicent
Macon
315.
Digital Meditation for Postoperative Pain Control after Abdominal Surgery for Cancer
Cancer Type
Solid Tumor
NCI ID
NCT05346692
Protocol IDs
EU5450-21
NCI-2022-01830
STUDY00003299
316.
Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT03233191
Protocol IDs
Treatment Sites (2)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
St. Joseph's /Candler Health System, INC
Savannah
Stephanie J. Reyes
912-819-5723
317.
Dinutuximab with Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children with Newly Diagnosed High Risk Neuroblastoma
Cancer Type
Neuroblastoma, Neurologocal Tumor
NCI ID
NCT06172296
Protocol IDs
ANBL2131
ANBL2131
NCI-2023-08530
318.
Division of Cancer Prevention NH-DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Cancer Type
Quality of Life
NCI ID
Protocol IDs
Treatment Sites (5)
Atrium Health Navicent
Macon
Cancer Center at DeKalb Medical Center
Decatur
Cathy Comer
404-501-7789
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
319.
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT04567420
Protocol IDs
DARE
NCI-2021-03770
320.
Docetaxel, Ramucirumab, and Pembrolizumab for the Treatment of Metastatic or Recurrent Non-small Cell Lung Cancer in Patients who have Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade Therapy
Cancer Type
Lung Cancer
NCI ID
NCT04340882
Protocol IDs
Treatment Sites (2)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Winship Cancer Institute of Emory University
Atlanta
321.
Donor Immune Cells (Allogenic Ex Vivo Expanded Gamma Delta T Cells), Dinutuximab, Temozolomide, Irinotecan and Zoledronate for the Treatment of Refractory, Relapsed, or Progressive Neuroblastoma in Children
Cancer Type
Neuroblastoma
NCI ID
NCT05400603
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
322.
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT03399799
Protocol IDs
CR108404
NCI-2018-00367
64407564MMY1001
2017-002400-26
323.
Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
Cancer Type
Melanoma
NCI ID
NCT05479812
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
324.
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Cancer Type
Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT04278768
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
325.
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT05552469
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
326.
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Unknown Primary
NCI ID
NCT05118841
Protocol IDs
ZX-4081
NCI-2022-02249
327.
Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients With r/r NHL and r/r B-cell ALL
Cancer Type
Cancer-Related Syndrome
NCI ID
NCT03666000
Protocol IDs
Treatment Sites (2)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
Winship Cancer Institute of Emory University
Atlanta
328.
Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
Cancer Type
Lung Cancer
NCI ID
NCT03833154
Protocol IDs
Treatment Sites (17)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
404-303-3355
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Decatur
Decatur
404-303-3355
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
329.
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients with Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04890236
Protocol IDs
Winship5085-20
NCI-2020-06380
STUDY00001001
330.
Duvelisib in Combination with Nivolumab for Treatment of Unresectable Stage IIIB-IV Melanoma
Cancer Type
Melanoma
NCI ID
NCT04688658
Protocol IDs
HCC 20-155
NCI-2021-13070
331.
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
Cancer Type
Anal Cancer, Unknown Primary
NCI ID
NCT04444921
Protocol IDs
Treatment Sites (1)
Lewis Hall Singletary Oncology Center at John D. Archbold Memorial Hospital
Thomasville
332.
Educational Interview in Improving Health Literacy in African-American Participants with Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT03322891
Protocol IDs
Treatment Sites (4)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Atlanta
Atlanta
Grady Memorial Hospital
Atlanta
333.
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Cancer Type
Solid Tumor
NCI ID
NCT03742895
Protocol IDs
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Winship Cancer Institute of Emory University
Atlanta
334.
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Cancer Type
Bladder Cancer
NCI ID
NCT03711032
Protocol IDs
Treatment Sites (2)
Advanced Urology - Alpharetta
Roswell
Emory University Hospital - Atlanta
Atlanta
335.
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Cancer Type
Bile Duct Cancer, Gallbladder Cancer
NCI ID
NCT06282575
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
336.
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients
Cancer Type
Melanoma
NCI ID
NCT03567889
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
337.
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Cancer Type
Neuroblastoma
NCI ID
NCT04301843
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
338.
EHR Tool in Assessing Heart Health among Cancer Survivors
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Prostate Cancer , Solid Tumor, Unknown Primary, Uterine Cancer
NCI ID
NCT03935282
Protocol IDs
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
339.
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
Cancer Type
Unknown Primary
NCI ID
NCT04620239
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
340.
Enfortumab Vedotin plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Cancer Type
Bladder Cancer
NCI ID
NCT05756569
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
341.
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Cancer Type
Lung Cancer
NCI ID
NCT06120140
Protocol IDs
Treatment Sites (1)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
342.
Ensartinib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Solid Tumor, Wilms Tumor
NCI ID
NCT03213652
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
343.
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Chemo-Immunotherapy with Pembrolizumab Before Surgery
Cancer Type
Breast Cancer
NCI ID
NCT05877859
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
344.
Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients
Cancer Type
Prostate Cancer
NCI ID
NCT06262139
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
345.
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Cancer Type
Thyroid Cancer
NCI ID
NCT05229341
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
346.
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) with the Contrast Agent Iohexol
Cancer Type
Solid Tumor
NCI ID
NCT03997370
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
347.
Evaluation of Human Immune Responses to Vaccination in Patients with Lymphoma
Cancer Type
Hematopoietic Malignancies, Leukemia, Non-Hodgkin Lymphoma
NCI ID
NCT03501576
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Atlanta
Atlanta
Winship Cancer Institute of Emory University
Atlanta
348.
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT05696626
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
349.
Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO Study
Cancer Type
Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
NCI ID
NCT04996706
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
350.
Evaluation of Sexual Toxicities in Women After Pelvic Radiotherapy
Cancer Type
Anal Cancer, Cervical Cancer, Colon/Rectal Cancer, Gynecologic Cancers, Solid Tumor, Uterine Cancer
NCI ID
NCT05394428
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
351.
Everolimus, Nelarabine, Cyclophosphamide, and Etoposide Phosphate in Treating Patients with Relapsed or Refractory T Cell Lymphoblastic Leukemia or Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT03328104
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
352.
Expanded Access Intermediate Size Treatment Protocol: Pritelivir for Immunocompromised Subjects With Treatment Resistant Herpes Simplex Virus Type 1 or 2
Cancer Type
NCI ID
NCT05844436
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
353.
Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT05346835
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
354.
Expanded Access Program for Axatilimab in Chronic Graft Versus Host Disease (GVHD)
Cancer Type
Graft Versus Host Disease
NCI ID
NCT05544032
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
355.
Expanded Access Program for OOS Obe-cel
Cancer Type
Leukemia
NCI ID
NCT06799221
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
356.
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
Cancer Type
Lymphoma
NCI ID
NCT05776160
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
357.
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Cancer Type
Leukemia, Lymphoma
NCI ID
NCT05776134
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
358.
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
Cancer Type
Bone Tumor, Breast Cancer, Lung Cancer, Prostate Cancer
NCI ID
NCT00882609
Protocol IDs
Treatment Sites (1)
Southcoast Health
Savannah
359.
Faith-Based African American Cancer Survivorship Storytelling
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT03082612
Protocol IDs
Treatment Sites (1)
Grady Memorial Hospital
Atlanta
360.
Fatigue Assessment in Patients with Breast Cancer Undergoing Chemotherapy, Surgery, or Radiation Therapy
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT02759549
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
361.
Fiber-Rich Foods for the Treatment of Obesity and Prevention of Colon Cancer
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT04780477
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
362.
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT05304962
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
363.
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT00785525
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
364.
Financial Difficulty in Patients with Blood Cancer
Cancer Type
Leukemia, Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT05212233
Protocol IDs
LCCC2063
NCI-2022-10367
365.
Financial Distress during Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States
Cancer Type
Leukemia
NCI ID
NCT04928599
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
366.
Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT04960787
Protocol IDs
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
367.
First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT05103046
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
368.
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
Cancer Type
Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Lung Cancer, Ovarian Cancer, Stomach/ Gastric Cancer
NCI ID
NCT03401385
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
369.
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Cancer Type
Leukemia
NCI ID
NCT05086315
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
370.
Fluciclovine F18 or Gallium Ga 68-labeled PSMA-11 PET/CT in Enhancing Outcomes in Patients with Prostate Adenocarcinoma
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT03762759
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Grady Memorial Hospital
Atlanta
Winship Cancer Institute of Emory University
Atlanta
371.
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT05614739
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
372.
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients with Resectable or Borderline Resectable Pancreatic Cancer
Cancer Type
Pancreatic Cancer, Unknown Primary
NCI ID
NCT06423326
Protocol IDs
WINSHIP6093-23
NCI-2024-02082
STUDY00006976
373.
Gene Expression in Blood Samples from High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT00967239
Protocol IDs
MC083I
NCI-2009-01112
CDR0000638644
NSABP-MC083I
374.
Genetic Information and Family Testing Platform to Facilitate Genetic Testing for Cancer Patients' Families, GIFT Study
Cancer Type
Solid Tumor
NCI ID
NCT05552664
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
375.
Genetic Testing in African Americans (GTM-I)
Cancer Type
Endometrial Cancer, Ovarian Cancer
NCI ID
NCT05591131
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
376.
Genetic Testing in Guiding Treatment for Patients with Brain Metastases
Cancer Type
Brain & Spinal Cord Tumor, Solid Tumor, Unknown Primary
NCI ID
NCT03994796
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
377.
Genetic Testing in Screening Patients with Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT03765736
Protocol IDs
ACCRU-GI-1611
NCI-2018-02862
378.
Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT02194738
Protocol IDs
Treatment Sites (26)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
404-303-3355
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Atrium Health Navicent
Macon
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Cancer Center at DeKalb Medical Center
Decatur
Cathy Comer
404-501-7789
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Decatur
Decatur
404-303-3355
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Gwinnett Medical Center
Lawrenceville
404-851-2340
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Low Country Cancer Care Associates, PC
Savannah
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
Piedmont Columbus Regional
Columbus
Winship Cancer Institute of Emory University
Atlanta
379.
Global Cardio Oncology Registry
Cancer Type
Breast Cancer, Hodgkin Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Plasma cell neoplasm, Solid Tumor, Unknown Primary
NCI ID
NCT05598879
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
380.
Head and Neck cancERs International cOviD-19 collabOraTion
Cancer Type
COVID-19, Head and Neck Cancer, Thyroid Cancer
NCI ID
NCT04632173
Protocol IDs
HERODOTUS
NCI-2021-11878
381.
Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy
Cancer Type
Hodgkin Lymphoma
NCI ID
NCT01790152
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
382.
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCI ID
NCT05659381
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
383.
Highest Dose of Uproleselan in Combination with Fludarabine and Cytarabine for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and that Expresses E-selectin Ligand on the Cell Membrane
Cancer Type
Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT05146739
Protocol IDs
PEPN2113
PEPN2113
NCI-2021-10020
PEPN2113-APAL2020C
384.
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Cancer Type
Cancer-Related Syndrome, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS)
NCI ID
NCT04904588
Protocol IDs
ACCESS
NCI-2021-06605
385.
Hormonal Therapy after Pertuzumab and Trastuzumab for the Treatment of Hormone Receptor Positive, HER2 Positive Breast Cancer, the ADEPT study
Cancer Type
Breast Cancer
NCI ID
NCT04569747
Protocol IDs
20-347
NCI-2020-13971
386.
HPVIQ-PedOnc Intervention in Maximizing HPV Vaccine Uptake in Young Cancer Survivors
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT04469569
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
387.
Hu8F4 in Treating Patients with Advanced Hematologic Malignancies
Cancer Type
Hematopoietic Malignancies, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT02530034
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
388.
Hypofractionated Proton or Photon Radiation Therapy for the Treatment of Brain Tumors, the HiPPI Study
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT04278118
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
389.
Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT04776395
Protocol IDs
WINSHIP5157-20
NCI-2020-08351
390.
IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma
Cancer Type
Melanoma
NCI ID
NCT05987332
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
391.
Identification of Treatment Concentrations of Defactinib or Avutometinib for the Treatment of Patients with Glioblastoma
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT05798507
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
392.
ILND Surgery Alone or after Chemotherapy with or without Radiation Therapy in Treating Patients with Advanced Penile Cancer
Cancer Type
Penile Cancer
NCI ID
NCT02305654
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
393.
Imaging and Blood Biomarker Evaluation of Engraftment after Allogeneic Hematopoietic Stem Cell Transplant, REVEAL Study
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT03541889
Protocol IDs
OUHSC4891-19
NCI-2020-13763
394.
Imatinib Mesylate and Combination Chemotherapy in Treating Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Cancer Type
Leukemia
NCI ID
NCT03007147
Protocol IDs
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
395.
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Cancer Type
Solid Tumor
NCI ID
NCT04871542
Protocol IDs
Treatment Sites (4)
John B Amos Cancer Center
Columbus
Courtney Dean Alexander
706-780-6201
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
396.
Immune Checkpoint Inhibitors with or without Propranolol Hydrochloride for the Treatment of Urothelial Cancer
Cancer Type
Unknown Primary
NCI ID
NCT04848519
Protocol IDs
WINSHIP5200-20
NCI-2021-00437
397.
Immunotherapy (Nivolumab and Ipilimumab) for the Treatment of Relapsed or Refractory INI-1 Negative Cancer
Cancer Type
Brain & Spinal Cord Tumor, Hematopoietic Malignancies, Sarcoma
NCI ID
NCT04416568
Protocol IDs
20-041
NCI-2020-04573
398.
Immunotherapy in Combination with Prednisone and Sirolimus for Kidney Transplant Recipients with Unresectable or Metastatic Skin Cancer
Cancer Type
Melanoma
NCI ID
NCT05896839
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
399.
Implementation and Effectiveness of HN-STAR in Managing the Health of Head and Neck Squamous Cell Cancer Survivors
Cancer Type
Head and Neck Cancer
NCI ID
NCT04208490
Protocol IDs
Treatment Sites (1)
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
400.
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Cancer Type
Solid Tumor
NCI ID
NCT05108298
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
401.
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
Cancer Type
Solid Tumor
NCI ID
NCT04301765
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
402.
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS=20 HNSCC
Cancer Type
Head and Neck Cancer, Unknown Primary
NCI ID
NCT06295731
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
403.
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Cancer Type
Leukemia
NCI ID
NCT04455841
Protocol IDs
INCB 00928-104
NCI-2020-08196
404.
Informational Meetings for Planning and Coordinating Treatment, The IMPACT Trial
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Sarcoma, Solid Tumor
NCI ID
NCT04330833
Protocol IDs
IUSCC-0705
NCI-2021-01462
405.
Inotuzumab Ozogamicin and Blinatumomab in Treating Patients with Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT03739814
Protocol IDs
A041703
A041703
NCI-2018-02484
406.
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia
Cancer Type
Leukemia
NCI ID
NCT03150693
Protocol IDs
Treatment Sites (2)
Georgia Cancer Center at Augusta University
Augusta
Winship Cancer Institute of Emory University
Atlanta
407.
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients with High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Cancer Type
Leukemia, Testicular Cancer
NCI ID
NCT03959085
Protocol IDs
Treatment Sites (3)
Atrium Health Navicent
Macon
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
408.
Inotuzumab Ozogamicin in Treating Younger Patients with B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT02981628
Protocol IDs
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
409.
Intensity-Modulated Proton Therapy in Treating Patients with Limited Stage or Extensive Stage Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT04342429
Protocol IDs
RAD4649-19
NCI-2019-02577
410.
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/?or Midline Gliomas
Cancer Type
Brain Tumor
NCI ID
NCT04617002
Protocol IDs
Treatment Sites (1)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
411.
International CIPN Assessment and Validation Study (ICAVS)
Cancer Type
NCI ID
NCT04633655
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
412.
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Cancer Type
Prostate Cancer
NCI ID
NCT03151629
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
413.
Intraoperative Radiation Therapy in Treating Patients with Breast Cancer Undergoing Breast-Conserving Surgery
Cancer Type
Breast Cancer
NCI ID
NCT01570998
Protocol IDs
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
414.
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
Cancer Type
Leukemia
NCI ID
NCT05519579
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
415.
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab with or without Eflornithine in Treating Patients with Relapsed or Refractory Neuroblastoma
Cancer Type
Neuroblastoma
NCI ID
NCT03794349
Protocol IDs
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
416.
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Cancer Type
Hematopoietic Malignancies, Unknown Primary
NCI ID
NCT04754945
Protocol IDs
Winship5086-20
NCI-2020-06548
417.
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT01042379
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Atlanta
Atlanta
Winship Cancer Institute of Emory University
Atlanta
418.
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Cancer Type
Sarcoma
NCI ID
NCT06127407
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
419.
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Cancer Type
Head and Neck Cancer, Unknown Primary
NCI ID
NCT04892173
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
420.
Ketorolac before Surgery for the Treatment of Stage I-II Non-small Cell Lung Cancer or Stage III Renal Cell Cancer
Cancer Type
Lung Cancer
NCI ID
NCT04495894
Protocol IDs
Treatment Sites (4)
Emory Clinic
Atlanta
Emory University Hospital - Atlanta
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
421.
KZR-261 in Subjects With Advanced Solid Malignancies
Cancer Type
Colon/Rectal Cancer, Eye Cancer, Melanoma, Prostate Cancer , Solid Tumor, Unknown Primary
NCI ID
NCT05047536
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
422.
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Cancer Type
Bladder Cancer, Unknown Primary
NCI ID
NCT04752722
Protocol IDs
EG-70-101
NCI-2021-12422
423.
Lenvatinib and Pembrolizumab before Surgery for the Treatment of Locally Advanced Non-Metastatic Kidney Cancer
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT04393350
Protocol IDs
Winship4955-20
NCI-2020-01064
424.
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplant
Cancer Type
Liver Cancer / Hepatoblastoma
NCI ID
NCT05103904
Protocol IDs
Winship5381-21
NCI-2021-07757
STUDY00003060
425.
Letrozole with and without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT05464810
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
426.
Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCI ID
NCT04095364
Protocol IDs
Treatment Sites (3)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
427.
Liquid Biopsy as a Prognostic and Response Diagnostic in Patients with Ewing Sarcoma and Osteosarcoma, LEOPARD Study
Cancer Type
Sarcoma
NCI ID
NCT06068075
Protocol IDs
18-138
NCI-2023-07461
428.
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Cancer Type
Solid Tumor
NCI ID
NCT03435796
Protocol IDs
GC-LTFU-001
NCI-2018-00957
U1111-1206-8250
2017-001465-24
429.
Long-Term Follow-up Study
Cancer Type
Unknown Primary
NCI ID
NCT05332054
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
430.
Long-term Follow-up Study of Allogeneic Gamma Delta (?d) CAR T Cells
Cancer Type
Lymphoma, Non-Hodgkin Lymphoma
NCI ID
NCT04911478
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
431.
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Cancer Type
NCI ID
NCT03486873
Protocol IDs
Treatment Sites (4)
Emory University School of Medicine
Atlanta
Georgia Cancer Center at Augusta University
Augusta
Northwest Georgia Oncology Centers - Cobb Hospital (Hiram)
Hiram
Kristine Parker, RN Clinical Research Director
770-281-5131
Northwest Georgia Oncology Centers - Tanner Medical Center Villa Rica
Carrollton
Kristine Parker, RN Clinical Research Director
770-281-5101
432.
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Cancer Type
Prostate Cancer
NCI ID
NCT05803941
Protocol IDs
Treatment Sites (1)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
433.
Losartan and Sunitinib for the Treatment of Relapsed or Refractory Osteosarcoma
Cancer Type
Sarcoma
NCI ID
NCT03900793
Protocol IDs
18-2740
NCI-2019-06119
18-2740.cc
434.
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT05493566
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
435.
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients with Multiple Myeloma
Cancer Type
Bone Tumor, Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT03858205
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
436.
LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT05900986
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
437.
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT03053193
Protocol IDs
Treatment Sites (6)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
Piedmont Cancer Institute - Atlanta
Atlanta
Katie Adams
678-298-3238
Piedmont Cancer Institute - Fayetteville
Fayetteville
678-298-3238
Piedmont Cancer Institute - Newnan
Newnan
Katie Adams
678-298-3238
Piedmont Cancer Institute - Stockbridge
Stockbridge
Katie Adams
678-298-3238
438.
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
Cancer Type
Unknown Primary
NCI ID
NCT06097728
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
439.
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Cancer Type
Melanoma
NCI ID
NCT03860883
Protocol IDs
Treatment Sites (3)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
St. Joseph's /Candler Health System, INC
Savannah
Stephanie J. Reyes
912-819-5723
440.
Melphalan before Stem Cell Transplant for the Treatment of Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT04483206
Protocol IDs
WINSHIP5001-20
NCI-2020-04920
STUDY00000449
441.
Message-Based Communication Outreach Intervention in Engaging Ovarian Cancer Survivors and Relatives to Consider Genetic Screening Services
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCI ID
NCT04927013
Protocol IDs
RSPH4984-20
NCI-2020-02281
STUDY00000224
442.
Metformin for the Prevention of Oral Cancer in Patients with Oral Leukoplakia or Erythroplakia
Cancer Type
Unknown Primary
NCI ID
NCT05237960
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
443.
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCI ID
NCT05445778
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
444.
Mobile Health for Adherence in Breast Cancer Patients
Cancer Type
Breast Cancer
NCI ID
NCT06112613
Protocol IDs
Treatment Sites (5)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
Winship Cancer Institute of Emory University
Atlanta
445.
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Cancer Type
Leukemia
NCI ID
NCT05429632
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
446.
Modified Immune Cells (Autologous iC9.GD2.CAR.IL-15 T cells) for Treating Patients with Relapsed or Refractory High Risk Neuroblastoma, Ganglioneuroblastoma, or Osteosarcoma
Cancer Type
Neuroblastoma, Neurologocal Tumor, Sarcoma
NCI ID
NCT03721068
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
447.
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
Cancer Type
Leukemia
NCI ID
NCT05224661
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
448.
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT05568472
Protocol IDs
Treatment Sites (3)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
449.
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT06586515
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
450.
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT04762199
Protocol IDs
WINSHIP5153-20
NCI-2020-08392
451.
Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
Cancer Type
Cancer-Related Syndrome, Unknown Primary
NCI ID
NCT03150914
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
452.
Myeloma-Developing Regimens Using Genomics (MyDRUG)
Cancer Type
Multiple Myeloma
NCI ID
NCT03732703
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
453.
MYELOMATCH: A Screening Study to Assign People with Myeloid Cancer to a Treatment Study or Standard of Care Treatment within myeloMATCH (MyeloMATCH Screening Trial)
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT05564390
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
454.
Nab-Paclitaxel and Gemcitabine Hydrochloride in Treating Teenagers or Young Adults with Recurrent or Refractory Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, or Soft Tissue Sarcoma
Cancer Type
Sarcoma
NCI ID
NCT02945800
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
455.
Nab-paclitaxel followed by Gemcitabine Hydrochloride in Treating Pediatric Participants with Newly-Diagnostic, Relapsed or Refractory Solid Tumors
Cancer Type
Solid Tumor
NCI ID
NCT03507491
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
456.
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults with Blood Cancers Undergoing Donor Stem Cell Transplant
Cancer Type
Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT03779854
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
457.
National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type
Leukemia, Lung Cancer, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor
NCI ID
NCT04314401
Protocol IDs
Treatment Sites (18)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
404-303-3355
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Decatur
Decatur
404-303-3355
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
458.
Natural Progesterone for the Treatment of Recurrent Glioblastoma
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT05091866
Protocol IDs
WINSHIP5184-20
NCI-2021-01498
STUDY00002155
459.
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Cancer Type
Neuroblastoma, Neurologocal Tumor
NCI ID
NCT05489887
Protocol IDs
Treatment Sites (2)
Augusta University Pediatric Cancer
Augusta
Georgia Cancer Center at Augusta University
Augusta
460.
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Cancer Type
Hematopoietic Malignancies, Melanoma
NCI ID
NCT03589339
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
461.
Nemtabrutinib with Rituximab for the Treatment of Patients with Mantle Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT06572618
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
462.
Neuroblastoma Biology Study
Cancer Type
Neuroblastoma
NCI ID
NCT01587300
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
463.
Niraparib and Panitumumab in Treating Patients with Advanced or Metastatic Colorectal Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT03983993
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
464.
Nivolumab and Ipilimumab in Treating Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
Cancer Type
Esophogeal Cancer
NCI ID
NCT03604991
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
465.
Nivolumab in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Cancer Type
NCI ID
NCT04759586
Protocol IDs
ANHL1931
ANHL1931
NCI-2021-01071
466.
Nivolumab in Treating Patients with Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT03816345
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
467.
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT05664217
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
468.
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT04656496
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
469.
Observation or Radiation Therapy in Treating Patients with Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT03180268
Protocol IDs
Treatment Sites (17)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
404-303-3355
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Emory Saint Joseph's Hospital
Atlanta
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Decatur
Decatur
404-303-3355
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Piedmont Fayette Hospital
Fayetteville
404-851-2340
Winship Cancer Institute of Emory University
Atlanta
470.
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
Cancer Type
Unknown Primary
NCI ID
NCT05919511
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
471.
Observational Study Protocol: LIVER-R
Cancer Type
NCI ID
NCT06252753
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
472.
Olanzapine versus Megestrol Acetate for the Treatment of Loss of Appetite among Advanced Cancer Patients
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT04939090
Protocol IDs
A222004
A222004
A222004
NCI-2021-03303
473.
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT05580562
Protocol IDs
ONC201-108
NCI-2023-02479
474.
ONC206 for the Treatment of Newly Diagnosed or Recurrent Diffuse Midline Gliomas or Other Recurrent Primary Malignant Central Nervous System Tumors
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT04732065
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
475.
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Cancer Type
Breast Cancer, Cervical Cancer, Esophogeal Cancer, Lung Cancer, Ovarian Cancer, Stomach/ Gastric Cancer
NCI ID
NCT06293898
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
476.
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Cancer Type
Multiple Myeloma
NCI ID
NCT04975997
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
477.
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients with Advanced Cancer
Cancer Type
Breast Cancer, Ovarian Cancer
NCI ID
NCT05735080
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
478.
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT05563220
Protocol IDs
Treatment Sites (2)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
479.
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients with Recurrent or Progressive Grade 2 or 3 Meningioma
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT02847559
Protocol IDs
Treatment Sites (1)
Piedmont Healthcare
Atlanta
480.
Optune Delivered Electric Field Therapy in Treating Children with Recurrent, Progressive, or Refractory High-Grade Glioma or Supratentorial Ependymoma
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT03033992
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
481.
Oral EPI-7386 in Patients With Castration-Resistant Prostate Cancer
Cancer Type
Prostate Cancer
NCI ID
NCT04421222
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
482.
Osimertinib in Treating Patients with Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Cancer Type
Lung Cancer
NCI ID
NCT03191149
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
483.
Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT04181060
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
484.
Palliative Radiotherapy with Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT05244239
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
485.
Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
Cancer Type
Unknown Primary
NCI ID
NCT05866302
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
486.
Paricalcitol and Hydroxychloroquine in Combination with Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced or Metastatic Pancreatic Cancer
Cancer Type
Pancreatic Cancer, Unknown Primary
NCI ID
NCT04524702
Protocol IDs
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Saint Joseph's Hospital of Atlanta
Atlanta
Winship Cancer Institute of Emory University
Atlanta
487.
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT04960579
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
488.
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
Cancer Type
Neuroblastoma, Neurologocal Tumor
NCI ID
NCT02559778
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
489.
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT04049669
Protocol IDs
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
490.
Peginterferon alfa-2b in Treating Younger Patients with Recurrent or Refractory and Radiographically or Clinically Progressive Pilocytic Astrocytomas and Optic Pathway Gliomas
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Cancer-Related Syndrome, Unknown Primary
NCI ID
NCT02343224
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
491.
Pembrolizumab and Cabozantinib in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Cancer That Cannot Be Removed by Surgery
Cancer Type
Head and Neck Cancer
NCI ID
NCT03468218
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
492.
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
Cancer Type
Prostate Cancer
NCI ID
NCT04848337
Protocol IDs
HCRN GU19-385
NCI-2021-06868
493.
Pembrolizumab in Treating Younger Patients with Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT02359565
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
494.
Pembrolizumab versus Observation in Patients with Early Stage Triple-Negative Breast Cancer who had a Pathologic Complete Response after Chemotherapy plus Pembrolizumab, OptimICE-PCR Trial
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT05812807
Protocol IDs
Treatment Sites (3)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
495.
Pembrolizumab with and without Intra-operative Radiation Therapy in Treating Patients with Triple Negative Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT02977468
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
496.
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT06422143
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
497.
Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients with Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer
Cancer Type
Stomach/ Gastric Cancer
NCI ID
NCT03257163
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
498.
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Cancer Type
Head and Neck Cancer
NCI ID
NCT04815720
Protocol IDs
VX15/2503-12
NCI-2021-10364
KEYNOTE B84
499.
Pepinemab with or without Ipilimumab and/or Nivolumab in Treating Patients with Stage I-IVA Head and Neck Squamous Cell Cancer
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03690986
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
500.
Perflutren Lipid Microspheres Ultrasound in Diagnosing Patients with Intraocular Tumors Undergoing Diagnostic Surgery
Cancer Type
Eye Cancer, Melanoma
NCI ID
NCT01930968
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
501.
Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients with Low Testosterone
Cancer Type
Unknown Primary
NCI ID
NCT04731376
Protocol IDs
EU5097-20
NCI-2020-06998
502.
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
Cancer Type
Leukemia
NCI ID
NCT04872478
Protocol IDs
2843-1003
NCI-2021-13604
503.
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Cancer Type
Head and Neck Cancer, Sarcoma, Solid Tumor
NCI ID
NCT04541108
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
504.
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Cancer Type
Colon/Rectal Cancer, Sarcoma, Solid Tumor
NCI ID
NCT03715933
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
505.
Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Lung Cancer
NCI ID
NCT05256290
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
506.
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT03785249
Protocol IDs
Treatment Sites (2)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
507.
Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT03761108
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
508.
Phase 2 Randomized, Double Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic Her2+ Breast Carcinoma (HER2CLIMB)
Cancer Type
Breast Cancer
NCI ID
Protocol IDs
ONT-380-206
509.
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Cancer Type
Lung Cancer
NCI ID
NCT04613596
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
510.
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
Cancer Type
Colon/Rectal Cancer, Lung Cancer
NCI ID
NCT06105021
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
511.
Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post-Infusion of T-Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells and With Post Transplant Cyclophosphamide
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT04237623
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
512.
Phase II Trial of Belumosudil and Rituximab for the Primary Treatment of Extensive Chronic Graft-versus-host Disease
Cancer Type
Graft Versus Host Disease
NCI ID
NCT06046248
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
513.
Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally Advanced Resected Head and Neck Cancer
Cancer Type
Head and Neck Cancer
NCI ID
NCT01311063
Protocol IDs
Treatment Sites (1)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
514.
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC = 50%) and Without Actionable Genomic Alterations
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT06357533
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
515.
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
Cancer Type
Kidney Cancer, Multiple Myeloma
NCI ID
NCT06142396
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
516.
Pilot Study of Neuropsychological and Behavioral Assessment in Children With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)
Cancer Type
Brain Tumor
NCI ID
NCT00772200
Protocol IDs
Treatment Sites (3)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
517.
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Cancer Type
Multiple Myeloma
NCI ID
NCT04126200
Protocol IDs
208887
NCI-2020-01127
518.
Poly ICLC for the Treatment of Progressive or Recurrent Low-Grade Gliomas in Children and Young Adults with Neurofibromatosis Type 1
Cancer Type
Brain & Spinal Cord Tumor, Cancer-Related Syndrome, Unknown Primary
NCI ID
NCT04544007
Protocol IDs
NF111
NCI-2022-03434
519.
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCI ID
NCT04365374
Protocol IDs
GTM-102
NCI-2021-03480
520.
Predicting Childhood Cancer Survivors' Transition Readiness and Transfer Outcomes, SURV Transfer Outcomes Study
Cancer Type
Solid Tumor
NCI ID
NCT04257058
Protocol IDs
CHOA4312-18
NCI-2020-07495
521.
Project: Every Child for Younger Patients with Cancer
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Leukemia, Neuroendocrine Tumor, Solid Tumor, Unknown Primary
NCI ID
NCT02402244
Protocol IDs
Treatment Sites (2)
Atrium Health Navicent
Macon
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
522.
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
Cancer Type
Prostate Cancer
NCI ID
NCT04995198
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
523.
Propranolol Hydrochloride and Pembrolizumab in Treating Patients with Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery
Cancer Type
Melanoma
NCI ID
NCT03384836
Protocol IDs
I 53217
NCI-2017-02210
524.
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Cancer Type
Multiple Myeloma
NCI ID
NCT01838512
Protocol IDs
Treatment Sites (2)
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
525.
Prospective Study of the Relationship between Chemotherapy Dose Intensity and Mortality in Early Stage (I-III) Breast Cancer Patients CABS
Cancer Type
Breast Cancer
NCI ID
Protocol IDs
526.
Protocol for a Research Sample Repository for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
Cancer Type
Unknown Primary
NCI ID
NCT04920474
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
527.
Proton Radiation Therapy for the Treatment of Patients with High Risk Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT04725903
Protocol IDs
RAD5131-20
NCI-2020-07113
528.
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Hodgkin Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma, Plasma cell neoplasm
NCI ID
NCT06665100
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
529.
PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT06074510
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
530.
Radiation Medication (Radium-223 dichloride) versus Radium-223 dichloride plus Radiation Enhancing Medication (M3814) versus Radium-223 dichloride plus M3814 plus Avelumab (a type of immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
Cancer Type
Bone Tumor
NCI ID
NCT04071236
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
531.
Radiation Therapy Alone, Radiation Therapy plus Leuprolide, or Radiation Therapy plus Relugolix for the Treatment of Non-metastatic Prostate Cancer
Cancer Type
Prostate Cancer
NCI ID
NCT05320406
Protocol IDs
RAD5484-21
NCI-2022-00117
STUDY00003654
532.
Radiation Therapy with or without Cisplatin in Treating Patients with Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Cancer Type
Head and Neck Cancer
NCI ID
NCT02734537
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
533.
Radiation Therapy with Protons or Photons in Treating Patients with Liver Cancer
Cancer Type
Liver Cancer / Hepatoblastoma
NCI ID
NCT03186898
Protocol IDs
NRG-GI003
NRG-GI003
NCI-2016-02009
NRG-GI003
534.
Radioligand Therapy after PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients with Biochemically Recurrent Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT06105918
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
535.
Radiosurgery before Surgery for the Treatment of Brain Metastases
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT04895592
Protocol IDs
RAD5234-21
NCI-2021-02761
STUDY00001896
536.
Reaching Rural Cancer Survivors Who Smoke
Cancer Type
Unknown Primary
NCI ID
NCT05008848
Protocol IDs
A211901
A211901
A211901
NCI-2021-03543
537.
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Cancer Type
Liver Cancer / Hepatoblastoma
NCI ID
NCT06486454
Protocol IDs
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
538.
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients with Newly Diagnosed WNT-Driven Medulloblastoma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary
NCI ID
NCT02724579
Protocol IDs
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
539.
Reduction of Donor Blood Transfusion in Patients During Surgery for in Patients with Locally Advanced Kidney Cancer
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT04922307
Protocol IDs
VICCURO2114
NCI-2021-10595
540.
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCI ID
NCT05870748
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
541.
Regional Radiation Therapy with or without Whole Breast Irradiation in Treating Patients with Estrogen Receptor Positive, HER2 Negative Low Risk Breast Cancer Who Have Undergone Breast Conserving Surgery or Mastectomy
Cancer Type
Breast Cancer
NCI ID
NCT03488693
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
542.
Registry of patients that have received the Caris Target Now and/or hematopoietic diagnostic testing
Cancer Type
Multiple Primaries
NCI ID
Caris
Protocol IDs
Caris
543.
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT04427384
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
544.
Registry Study for Radiation Therapy Outcomes
Cancer Type
Solid Tumor
NCI ID
NCT01255748
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
545.
Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
Cancer Type
Liver Cancer / Hepatoblastoma, Unknown Primary
NCI ID
NCT05194293
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
546.
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCI ID
NCT05257408
Protocol IDs
Treatment Sites (2)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Winship Cancer Institute of Emory University
Atlanta
547.
Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Cancer Type
Ovarian Cancer
NCI ID
NCT05998135
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
548.
Research Study of Clinical, Genetic, and Biological Factors as Prognostic Values in Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Cancer Type
Neuroblastoma
NCI ID
NCT00904241
Protocol IDs
Treatment Sites (4)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Augusta University Pediatric Cancer
Augusta
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
549.
REtroperitoneal SArcoma Registry: an International Prospective Initiative
Cancer Type
Sarcoma
NCI ID
NCT03838718
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
550.
Rifaximin in Preventing Infections in Participants with Blood Cancer Undergoing Hematopoietic Stem Cell Transplantation
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT03529825
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
551.
Rifaximin in Treating Patients with Monoclonal Gammopathy
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT03820817
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
552.
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Cancer Type
Bile Duct Cancer, Gallbladder Cancer
NCI ID
NCT06109779
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
553.
Rituximab with or without Stem Cell Transplant in Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT03267433
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
554.
Robotic vs. Open NSM for Early Stage Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT05720039
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
555.
S1400F Funding Placeholder
Cancer Type
NCI ID
Protocol IDs
S1400F
556.
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Cancer Type
Unknown Primary, Uterine Cancer
NCI ID
NCT06132958
Protocol IDs
Treatment Sites (2)
Georgia Cancer Center at Augusta University
Augusta
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
557.
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT06074588
Protocol IDs
Treatment Sites (1)
Northwest Georgia Oncology Centers (NGOC) - Cobb Hospital (Marietta)
Marietta
Kristine Parker, RN Clinical Research Director
770-281-5101
558.
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
Cancer Type
Breast Cancer
NCI ID
NCT04650451
Protocol IDs
BPX603-201A
NCI-2021-00052
559.
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
Cancer Type
Prostate Cancer
NCI ID
NCT02744287
Protocol IDs
BP-012
NCI-2019-02615
560.
Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)
Cancer Type
Leukemia
NCI ID
NCT04416984
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
561.
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
Cancer Type
Leukemia
NCI ID
NCT03793478
Protocol IDs
AC220-A-U202
NCI-2019-02948
2016-002919-18
562.
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor
NCI ID
NCT02704858
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
563.
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Cancer Type
Leukemia
NCI ID
NCT06001788
Protocol IDs
Treatment Sites (2)
Georgia Cancer Center at Augusta University
Augusta
Winship Cancer Institute of Emory University
Atlanta
564.
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT04279847
Protocol IDs
INCB 57643-103
NCI-2020-07097
565.
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
Cancer Type
Unknown Primary
NCI ID
NCT01656603
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
566.
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer
NCI ID
NCT04140526
Protocol IDs
ONC-392-001
R44CA250824-01
NCI-2020-06149
20193108
4R44CA250824-02
567.
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
Cancer Type
Lung Cancer, Solid Tumor
NCI ID
NCT06014658
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
568.
Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease
Cancer Type
Solid Tumor
NCI ID
NCT06343792
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
569.
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
Cancer Type
Lung Cancer, Lymphoma, Melanoma
NCI ID
NCT04137900
Protocol IDs
TAB004-01
NCI-2020-00511
570.
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Cancer Type
Prostate Cancer
NCI ID
NCT06120491
Protocol IDs
Treatment Sites (4)
Piedmont Cancer Institute - Atlanta
Atlanta
Katie Adams
678-298-3238
Piedmont Cancer Institute - Fayetteville
Fayetteville
678-298-3238
Piedmont Cancer Institute - Newnan
Newnan
Katie Adams
678-298-3238
Piedmont Cancer Institute - Stockbridge
Stockbridge
Katie Adams
678-298-3238
571.
Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT02636855
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
572.
Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
Cancer Type
Liver Cancer / Hepatoblastoma
NCI ID
NCT04736121
Protocol IDs
STX2001
NCI-2021-13336
573.
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial
Cancer Type
Cervical Cancer
NCI ID
NCT06498661
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
574.
Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Cancer Type
Unknown Primary, Uterine Cancer
NCI ID
NCT05611931
Protocol IDs
Treatment Sites (2)
Georgia Cancer Center at Augusta University
Augusta
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
575.
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT05929768
Protocol IDs
Treatment Sites (3)
Lewis Hall Singletary Oncology Center at John D. Archbold Memorial Hospital
Thomasville
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
576.
Sirolimus and Metronomic Chemotherapy for the Treatment of High-Risk Solid Tumors in Children, AflacST1903 Study
Cancer Type
Sarcoma, Solid Tumor
NCI ID
NCT04469530
Protocol IDs
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Winship Cancer Institute of Emory University
Atlanta
577.
Sirolimus and Metronomic Chemotherapy in Treating Younger Patients with Recurrent and/or Refractory Solid or Central Nervous System Tumors
Cancer Type
Solid Tumor
NCI ID
NCT02574728
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
578.
Smoke-Free Homes Intervention for the Prevention of Smoking
Cancer Type
Unknown Primary
NCI ID
NCT04547686
Protocol IDs
SFH-5A-RCT
NCI-2021-01784
STUDY00001085
579.
Soccer-Based Lifestyle in Improving Bone and Metabolic Health in Prostate Cancer Survivors
Cancer Type
Prostate Cancer
NCI ID
NCT04144127
Protocol IDs
RSPH4684-19
NCI-2019-05183
IRB00110890
580.
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT04185883
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
581.
SpaceIT Hydrogel System for Perirectal Spacing
Cancer Type
Prostate Cancer
NCI ID
NCT06451614
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
582.
Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients with Brain Tumors
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCI ID
NCT04908709
Protocol IDs
RAD4500-18
NCI-2018-02065
IRB00106849
583.
Standard Chemotherapy in Treating Young Patients with Medulloblastoma or Other Central Nervous System Embryonal Tumors
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Neuroblastoma, Neurologocal Tumor
NCI ID
NCT02875314
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
584.
Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab for the Treatment of Locally Advanced or Metastatic Cancer
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT04295863
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
585.
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors with NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Cancer Type
Melanoma
NCI ID
NCT05341349
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
586.
Stereotactic Radiosurgery or Hippocampus Avoidance Whole-Brain Radiation Therapy with Memantine in Treating Patients with 5 or more Brain Metastases
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCI ID
NCT03550391
Protocol IDs
Treatment Sites (2)
Emory Saint Joseph's Hospital
Atlanta
Winship Cancer Institute of Emory University
Atlanta
587.
STK-012 Monotherapy and in Combination Therapy in Patients with Solid Tumors
Cancer Type
Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Solid Tumor, Unknown Primary
NCI ID
NCT05098132
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
588.
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT06158841
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
589.
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Cancer Type
Lung Cancer
NCI ID
NCT06211036
Protocol IDs
Treatment Sites (2)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
590.
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Cancer Type
Prostate Cancer
NCI ID
NCT04221542
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
591.
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
Cancer Type
Multiple Myeloma
NCI ID
NCT05396885
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
592.
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT06297226
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
593.
Study of AZD0754 in Participants With Metastatic Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT06267729
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
594.
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
Cancer Type
Breast Cancer
NCI ID
NCT06428396
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
595.
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Cancer Type
Leukemia
NCI ID
NCT03013998
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
596.
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Cancer Type
Leukemia, Multiple Myeloma
NCI ID
NCT05153330
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
597.
Study of Chemotherapy, with or without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
Cancer Type
Gallbladder Cancer
NCI ID
NCT05564403
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
598.
Study of CHS-114 in Participants With Advanced Solid Tumors
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Solid Tumor, Unknown Primary
NCI ID
NCT05635643
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
599.
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
Cancer Type
Colon/Rectal Cancer, Lung Cancer
NCI ID
NCT05631574
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
600.
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Cancer Type
Bladder Cancer, Unknown Primary
NCI ID
NCT04452591
Protocol IDs
CG3002S
NCI-2021-01691
601.
Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT05905328
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
602.
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Cancer Type
Leukemia
NCI ID
NCT04260022
Protocol IDs
Treatment Sites (2)
Georgia Cancer Center at Augusta University
Augusta
Winship Cancer Institute of Emory University
Atlanta
603.
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Cancer Type
Lung Cancer, Melanoma, Stomach/ Gastric Cancer
NCI ID
NCT04198766
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
604.
Study of INCB123667 in Subjects With Advanced Solid Tumors
Cancer Type
Esophogeal Cancer, Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Stomach/ Gastric Cancer
NCI ID
NCT05238922
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
605.
Study of Key Late-Occurring Complications in Childhood Cancer Survivors
Cancer Type
Multiple Primaries
NCI ID
NCT00082745
Protocol IDs
Treatment Sites (3)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Augusta University Pediatric Cancer
Augusta
606.
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
Cancer Type
NCI ID
NCT04989803
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
607.
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
Cancer Type
Cervical Cancer, Unknown Primary
NCI ID
NCT03108495
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
608.
Study of Long-Term Follow-Up in Patients Who Have Participated in Children's Oncology Group Studies
Cancer Type
Multiple Primaries
NCI ID
NCT00736749
Protocol IDs
Treatment Sites (3)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Augusta University Pediatric Cancer
Augusta
609.
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Cancer Type
Lung Cancer
NCI ID
NCT04956640
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
610.
Study of LYL314 in Aggressive Large B-Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT05826535
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
611.
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Cancer Type
Unknown Primary, Uterine Cancer
NCI ID
NCT05797831
Protocol IDs
KRT-232-118
NCI-2024-03038
ENGOT en-21
GOG-3089
612.
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT05079282
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
613.
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Cancer Type
Hematopoietic Malignancies, Leukemia
NCI ID
NCT02074839
Protocol IDs
AG120-C-001
NCI-2014-00720
614.
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Cancer Type
Colon/Rectal Cancer, Gynecologic Cancers
NCI ID
NCT02628067
Protocol IDs
Treatment Sites (3)
Georgia Cancer Center for Excellence at Grady
Atlanta
Scott Edelman
404-489-9000
South Atlanta Hematology Oncology - Riverdale
Riverdale
615.
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT06760637
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
616.
Study of PYX-106 in Solid Tumors
Cancer Type
Uterine Cancer
NCI ID
NCT05718557
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
617.
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
Cancer Type
Lung Cancer
NCI ID
NCT04310020
Protocol IDs
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
618.
Study of Renal Tumors in Pediatric Patients
Cancer Type
Kidney Cancer
NCI ID
NCT00898365
Protocol IDs
Treatment Sites (5)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Atrium Health Navicent
Macon
Augusta University Pediatric Cancer
Augusta
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
619.
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
Cancer Type
Neuroendocrine Tumor, Unknown Primary
NCI ID
NCT05477576
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
620.
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Cancer Type
Unknown Primary
NCI ID
NCT03547973
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
621.
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
Cancer Type
Unknown Primary, Uterine Cancer
NCI ID
NCT06486441
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
622.
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Cancer Type
Breast Cancer
NCI ID
NCT05633654
Protocol IDs
Treatment Sites (4)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Northwest Georgia Oncology Centers (NGOC) - Cobb Hospital (Marietta)
Marietta
Kristine Parker, RN Clinical Research Director
770-281-5101
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
623.
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Cancer Type
Cervical Cancer, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Melanoma, Sarcoma, Skin Cancer (Non-Melanoma), Solid Tumor, Unknown Primary
NCI ID
NCT05103345
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
624.
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
Cancer Type
Leukemia
NCI ID
NCT06073821
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
625.
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT06252649
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
626.
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT04245397
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
627.
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Cancer Type
Brain & Spinal Cord Tumor, Hematopoietic Malignancies, Lymphoma, Unknown Primary
NCI ID
NCT04947319
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
628.
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DO-01)
Cancer Type
Ovarian Cancer
NCI ID
NCT06819007
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
629.
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Ovarian Cancer
NCI ID
NCT02715284
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
630.
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Cancer Type
Cervical Cancer, Unknown Primary
NCI ID
NCT06079671
Protocol IDs
D7984C00002
NCI-2024-05317
165663
2023-504374-38-00
ENGOT-cx19/GEICO
GOG-3092
631.
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT05433142
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
632.
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Unknown Primary
NCI ID
NCT06082167
Protocol IDs
Treatment Sites (1)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
633.
Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT05067257
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
634.
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT04879043
Protocol IDs
HDP-101-01
NCI-2021-04304
635.
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Cancer Type
Multiple Myeloma, Non-Hodgkin Lymphoma
NCI ID
NCT04756726
Protocol IDs
CFT7455-1101
NCI-2021-05587
636.
Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer
Cancer Type
Stomach/ Gastric Cancer
NCI ID
NCT04725994
Protocol IDs
ID-VDP-103
NCI-2021-09611
637.
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT06356129
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
638.
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
Cancer Type
Bladder Cancer, Kidney Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer
NCI ID
NCT06632951
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
639.
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT06236438
Protocol IDs
Treatment Sites (1)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
640.
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT05168566
Protocol IDs
Treatment Sites (2)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
641.
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT04428788
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
642.
Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04315324
Protocol IDs
S1905
S1905
NCI-2020-00768
643.
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT05317416
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
644.
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT05676931
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
645.
Studying the Effect of Levocarnitine in Protecting the Liver from Chemotherapy for Leukemia or Lymphoma
Cancer Type
Leukemia, Non-Hodgkin Lymphoma
NCI ID
NCT05602194
Protocol IDs
ACCL1931
ACCL1931
COG-ACCL1931
NCI-2022-08058
646.
Sublobar Resection or Stereotactic Ablative Radiotherapy in Treating Patients with Stage I Non-small Cell Lung Cancer, The STABLE-MATES Trial
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT02468024
Protocol IDs
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
647.
SurvivorLink in Improving Quality of Life in Cancer Survivors and Caregivers
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT03543852
Protocol IDs
RSPH-AFLAC4297-18
NCI-2018-00396
IRB00101506
648.
SynKIR-310 for Relapsed/Refractory B-NHL
Cancer Type
NCI ID
NCT06544265
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
649.
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT03394365
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
650.
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT05910801
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
651.
Talazoparib for the Treatment of BRCA 1/2 Mutant Metastatic Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT03990896
Protocol IDs
19-188
NCI-2019-07732
652.
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type
Multiple Myeloma, Non-Hodgkin Lymphoma, Plasma cell neoplasm
NCI ID
NCT02693535
Protocol IDs
Treatment Sites (3)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Winship Cancer Institute of Emory University
Atlanta
653.
Targeted Therapy Directed by Genetic Testing in Treating Patients with Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer
NCI ID
NCT05564377
Protocol IDs
EAY191
EAY191
NCI-2022-06842
654.
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Liver Cancer / Hepatoblastoma, Neuroblastoma, Non-Hodgkin Lymphoma, Sarcoma, Wilms Tumor
NCI ID
NCT03155620
Protocol IDs
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
655.
Targeted Treatment for Advanced Non-Small Cell Lung Cancer that has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Cancer Type
Lung Cancer
NCI ID
NCT06031688
Protocol IDs
Treatment Sites (2)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
656.
Targeted Treatment for Advanced Non-Small Cell Lung Cancer that Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Cancer Type
Lung Cancer
NCI ID
NCT06116682
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
657.
TAS102 and Liposomal Irinotecan in Treating Patients with Gastrointestinal Cancers That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Cancer Type
Bile Duct Cancer
NCI ID
NCT03368963
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
658.
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Cancer Type
Breast Cancer
NCI ID
NCT04457596
Protocol IDs
Treatment Sites (4)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
659.
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Cancer Type
Brain Tumor, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Melanoma, Neuroblastoma, Non-Hodgkin Lymphoma, Ovarian Cancer, Sarcoma, Uterine Cancer, Wilms Tumor
NCI ID
NCT04851119
Protocol IDs
PEPN2011
PEPN2011
NCI-2021-02852
660.
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults who are Undergoing Surgery for Lung Cancer and their Caregivers
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT06196008
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
661.
Testing CC-486 (Oral Azacitidine) plus the Standard Drug Therapy in Patients 75 years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma
Cancer Type
Lymphoma
NCI ID
NCT04799275
Protocol IDs
S1918
S1918
NCI-2020-01256
662.
Testing Continuous versus Intermittent Treatment with the Study Drug Zanubrutinib for Older Patients with Previously Untreated Mantle Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT05976763
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
663.
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Cancer Type
Ovarian Cancer, Uterine Cancer
NCI ID
NCT05950464
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
664.
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCI ID
NCT01810913
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
665.
Testing Drug Treatments after CAR T-cell Therapy in Patients with Diffuse Large B-cell Lymphoma That Has Come Back or Not Responded to Treatment
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT05633615
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
666.
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
Cancer Type
Lung Cancer
NCI ID
NCT04804644
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
667.
Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCI ID
NCT03811015
Protocol IDs
Treatment Sites (5)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
Winship Cancer Institute of Emory University
Atlanta
668.
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients with Cancer That Has Spread to the Brain
Cancer Type
Breast Cancer, Lung Cancer, Melanoma
NCI ID
NCT06500455
Protocol IDs
NRG-BN013
NRG-BN013
NCI-2024-04812
669.
Testing Nivolumab with or without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Cancer Type
Unknown Primary, Uterine Cancer
NCI ID
NCT05112601
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
670.
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Cancer Type
Kidney Cancer
NCI ID
NCT04981509
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
671.
Testing Olaparib and Temozolomide versus the Usual Treatment for Uterine Leiomyosarcoma after Chemotherapy Has Stopped Working
Cancer Type
Sarcoma, Unknown Primary, Uterine Cancer
NCI ID
NCT05432791
Protocol IDs
A092104
A092104
NCI-2022-05065
NCT05432791
672.
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy versus Standard of Care Chemotherapy Alone for Patients with Unresectable Colorectal Liver Metastases: The PUMP Trial
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT05863195
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
673.
Testing Sacituzumab Govitecan Therapy in Patients with HER2-Negative Breast Cancer and Brain Metastases
Cancer Type
Breast Cancer
NCI ID
NCT04647916
Protocol IDs
S2007
S2007
NCI-2020-07706
674.
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases.
Cancer Type
Brain Tumor, Breast Cancer
NCI ID
NCT04647916
Protocol IDs
S2007
NCI-2020-07706
675.
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients with High Risk Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT05946213
Protocol IDs
Treatment Sites (4)
Emory Proton Therapy Center
Atlanta
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
676.
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People with High-Risk Neuroblastoma (NBL)
Cancer Type
Neuroblastoma, Neurologocal Tumor
NCI ID
NCT03126916
Protocol IDs
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
677.
Testing the Addition of a Blood Pressure Medication, Carvedilol, to HER-2 Targeted Therapy for Metastatic Breast Cancer to Prevent Cardiac Toxicity
Cancer Type
Breast Cancer
NCI ID
NCT03418961
Protocol IDs
Treatment Sites (18)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
404-303-3355
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Decatur
Decatur
404-303-3355
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
678.
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial
Cancer Type
Lung Cancer
NCI ID
NCT04267848
Protocol IDs
Treatment Sites (19)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
404-303-3355
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Decatur
Decatur
404-303-3355
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
679.
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) after Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT05610163
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
680.
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (“EPOCH”) for Adult T-Cell Leukemia-Lymphoma (ATL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04301076
Protocol IDs
10335
10335
NCI-2020-01535
681.
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors that have Returned after Previous Treatment
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCI ID
NCT05432804
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
682.
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy after Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Cancer Type
Head and Neck Cancer
NCI ID
NCT06029270
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
683.
Testing the Addition of Chemotherapy to the Usual Treatment of Ovarian Function Suppression plus Hormonal Therapy in Premenopausal ER-Positive/HER2-Negative Breast Cancer Patients Who Are At High Risk of Cancer Returning, OFSET Trial
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT05879926
Protocol IDs
Treatment Sites (4)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
684.
Testing the Addition of Daratumumab-Hyaluronidase to Enhance Therapeutic Effectiveness of Lenalidomide in Smoldering Multiple Myeloma, The DETER-SMM Trial
Cancer Type
Multiple Myeloma
NCI ID
NCT03937635
Protocol IDs
Treatment Sites (1)
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
685.
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04803201
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Georgia Cancer Center at Augusta University
Augusta
Winship Cancer Institute of Emory University
Atlanta
686.
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT05624996
Protocol IDs
Treatment Sites (2)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Emory Proton Therapy Center
Atlanta
687.
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCI ID
NCT05276973
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
688.
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients with Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Cancer Type
Head and Neck Cancer, Unknown Primary
NCI ID
NCT04533750
Protocol IDs
NRG-HN008
NRG-HN008
NCI-2020-06481
689.
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy before Surgery for Patients with High-Grade Upper Urinary Tract Cancer
Cancer Type
Unknown Primary
NCI ID
NCT04628767
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
690.
Testing the Addition of Nivolumab to Standard Treatment for Patients with Metastatic or Unresectable Colorectal Cancer that have a BRAF Mutation
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT05308446
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
691.
Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients who are PD-L1 Negative
Cancer Type
Lung Cancer
NCI ID
NCT04929041
Protocol IDs
Treatment Sites (2)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
692.
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Cancer Type
Lung Cancer
NCI ID
NCT04402788
Protocol IDs
Treatment Sites (5)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Georgia Cancer Center for Excellence at Grady
Atlanta
Scott Edelman
404-489-9000
Saint Joseph's Hospital of Atlanta
Atlanta
Winship Cancer Institute of Emory University
Atlanta
693.
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment with the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
Cancer Type
Unknown Primary, Uterine Cancer
NCI ID
NCT05538897
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
694.
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma that has Progressed on the Usual Treatment
Cancer Type
Melanoma
NCI ID
NCT04557956
Protocol IDs
10285
10285
NCI-2020-07044
695.
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT05095376
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
696.
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy after Surgery for Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT04134260
Protocol IDs
NRG-GU008
NRG-GU008
NCI-2019-06838
697.
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients with Early Non-small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT04214262
Protocol IDs
S1914
S1914
NCI-2019-08627
698.
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
Cancer Type
Prostate Cancer
NCI ID
NCT05053152
Protocol IDs
Treatment Sites (1)
Piedmont Columbus Regional
Columbus
699.
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT05673148
Protocol IDs
Treatment Sites (1)
Emory Proton Therapy Center
Atlanta
700.
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Cancer Type
Uterine Cancer
NCI ID
NCT05256225
Protocol IDs
Treatment Sites (4)
Bluffton Campus at St. Joseph's/Candler
Bluffton
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
St. Joseph's /Candler Health System, INC
Savannah
Stephanie J. Reyes
912-819-5723
St. Joseph's /Candler Health System, INC
Savannah
701.
Testing the Anti-Cancer Drug Darolutamide in Patients with Testosterone-driven Salivary Gland Cancers
Cancer Type
Head and Neck Cancer
NCI ID
NCT05669664
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
702.
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients with Advanced Solid Tumors, The ComBET Trial
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT05327010
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
703.
Testing the Combination of two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
Cancer Type
Neuroendocrine Tumor, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT05947500
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
704.
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Cancer Type
Bladder Cancer, Kidney Cancer, Penile Cancer, Urethral Cancer
NCI ID
NCT03866382
Protocol IDs
Treatment Sites (4)
Emory Johns Creek Hospital
Johns Creek
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
705.
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients with High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Cancer Type
Leukemia
NCI ID
NCT05554406
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
706.
Testing the Role of DNA Released from Tumor Cells into the Blood in Guiding the Use of Immunotherapy after Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study
Cancer Type
Bladder Cancer, Unknown Primary
NCI ID
NCT05987241
Protocol IDs
Treatment Sites (6)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Emory Johns Creek Hospital
Johns Creek
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
707.
Testing the Safety and Benefit of Adding Hydroxychloroquine to Dabrafenib and/or Trametinib in Children with Recurrent or Progressive Low Grade or High Grade Brain Tumor with Specific Genetic Mutations
Cancer Type
Brain & Spinal Cord Tumor, Cancer-Related Syndrome, Unknown Primary
NCI ID
NCT04201457
Protocol IDs
PBTC-055
PBTC-055
NCI-2019-06216
708.
Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial
Cancer Type
Lung Cancer
NCI ID
NCT03801902
Protocol IDs
Treatment Sites (4)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
709.
Testing the Safety, Tolerability and Immunological Effects of SurVaxM in Children and Young Adults with Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor
NCI ID
NCT04978727
Protocol IDs
PBTC-060
PBTC-060
NCI-2021-07694
710.
Testing the use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy with Docetaxel plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Cancer Type
Head and Neck Cancer
NCI ID
NCT05408845
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
711.
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT05710406
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
712.
Testing the Use of Chemotherapy after Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Cancer Type
Neuroendocrine Tumor, Unknown Primary
NCI ID
NCT05040360
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
713.
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab with or without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
Cancer Type
Head and Neck Cancer
NCI ID
NCT05063552
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
714.
Testing the Use of Steroids and Tyrosine Kinase Inhibitors with Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Cancer Type
NCI ID
NCT04530565
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
715.
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Cancer Type
Lung Cancer
NCI ID
NCT04625647
Protocol IDs
S1900E
S1900E
NCI-2020-08103
716.
Testing the Use of the Usual Chemotherapy before and after Surgery for Removable Pancreatic Cancer
Cancer Type
Pancreatic Cancer
NCI ID
NCT04340141
Protocol IDs
Treatment Sites (2)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
717.
Testing the Usual Treatment of Radiation Therapy and HER2-Targeted Therapy to HER2-Targeted Therapy Alone for Low-Risk HER2-Positive Breast Cancer, The HERO Trial
Cancer Type
Breast Cancer
NCI ID
NCT05705401
Protocol IDs
Treatment Sites (2)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
718.
Testing the Usual Treatment of Radiation Therapy and Hormonal Therapy to Hormonal Therapy alone for Low-Risk, Early Stage Breast Cancer, the DEBRA Trial
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT04852887
Protocol IDs
Treatment Sites (2)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
719.
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy with Radiation after Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Unknown Primary
NCI ID
NCT04671667
Protocol IDs
EA3191
EA3191
NCI-2020-13174
720.
Testing Whether the Use of Brain Scans Alone Instead of Brain Scans plus Preventive Brain Radiation Affects Lifespan in Patients with Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT04155034
Protocol IDs
Treatment Sites (4)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
John B Amos Cancer Center
Columbus
Courtney Dean Alexander
706-780-6201
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
721.
TGRX-678 US Phase I for Subjects With Refractory or Advanced Chronic Myelogenous Leukemia
Cancer Type
Leukemia
NCI ID
NCT06088888
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
722.
The Effect of Low Frequency Soundwave Stimulation on Chemotherapy Induced Peripheral Neuropathy
Cancer Type
NCI ID
NCT05980169
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
723.
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children with Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children’s Oncology Group Study
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT04726241
Protocol IDs
APAL2020SC
APAL2020SC
NCI-2021-00056
724.
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Plasma cell neoplasm
NCI ID
NCT03805789
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
725.
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT04768868
Protocol IDs
IMP7068 - 101
NCI-2021-13607
726.
The Use of the LuViva Advanced Cervical Scan to Identify Women at High-Risk for Cervical Neoplasia
Cancer Type
NCI ID
NCT04915495
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
727.
Therapeutic Immune Cells (Gamma-Primed Mesenchymal Stromal Cells) for the Prevention of Acute Graft versus Host Disease after Donor Stem Cell Transplant in Patients with Blood Cancers or Myelodysplastic Syndrome
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT04328714
Protocol IDs
CHOA4439-18
NCI-2022-01159
728.
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
Cancer Type
Sarcoma
NCI ID
NCT05235165
Protocol IDs
AOST2031
AOST2031
NCI-2021-14237
729.
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Kidney Cancer, Sarcoma, Solid Tumor
NCI ID
NCT05286801
Protocol IDs
PEPN2121
PEPN2121
NCI-2022-01992
730.
Tissue Collection and Natural History Study of Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasms
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT02775383
Protocol IDs
Treatment Sites (14)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
404-303-3355
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Decatur
Decatur
404-303-3355
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
731.
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Cancer Type
Lung Cancer
NCI ID
NCT05468489
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
732.
Tolinapant and Radiation Therapy for the Treatment of Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
Cancer Type
Head and Neck Cancer
NCI ID
NCT05245682
Protocol IDs
WINSHIP5380-21
NCI-2021-09678
STUDY00002992
733.
Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients with Stage I-III Early Stage Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT05368428
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
734.
Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma
Cancer Type
Sarcoma
NCI ID
NCT04616560
Protocol IDs
PEPN1924
NCI-2020-08428
PEPN1924
735.
Treatment Response and Biomarker-Guided Steroid Taper for Children with GVHD
Cancer Type
Unknown Primary
NCI ID
NCT05090384
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
736.
Treosulfan-Based Conditioning Regimen before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT04965597
Protocol IDs
RG1121820
NCI-2021-13862
BMT CTN 1904
737.
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT02495415
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
738.
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Cancer Type
Bladder Cancer, Unknown Primary
NCI ID
NCT06510374
Protocol IDs
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
739.
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
Cancer Type
Lung Cancer
NCI ID
NCT06635824
Protocol IDs
Treatment Sites (1)
University Cancer and Blood Center, LLC - Athens Radiation Oncology
Athens
740.
Tumor Treating Fields for the Treatment of Brainstem Gliomas
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT05310448
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
741.
Two Studies for Patients with High Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a High Gene Risk Score, The PREDICT-RT Trial
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT04513717
Protocol IDs
Treatment Sites (4)
Bluffton Campus at St. Joseph's/Candler
Bluffton
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
St. Joseph's /Candler Health System, INC
Savannah
Stephanie J. Reyes
912-819-5723
St. Joseph's /Candler Health System, INC
Savannah
742.
Two Studies for Patients with Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a Higher Gene Risk Score, The Guidance Trial
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT05050084
Protocol IDs
Treatment Sites (2)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
743.
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT03260491
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
744.
Use of a Genomic Tumor Board to Increase the Number of Patients with Recurrent, Refractory, Metastatic, or Newly Diagnosed Advanced Solid Tumors who Receive Genome-Informed Treatment
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT05455606
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
745.
Use of Lymphatic Mapping to Guide Radiotherapy to the Neck in Oropharyngeal Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCI ID
NCT05451004
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
746.
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients with Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
Cancer Type
Melanoma
NCI ID
NCT04462406
Protocol IDs
Treatment Sites (2)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Summit Cancer Care at the Nancy N. Lewis and J.C. Lewis Cancer & Research Pavilion
Savannah
747.
Using Cancer Cells in the Blood (ctDNA) to Determine the Type of Chemotherapy that will Benefit Patients who Have Had Surgery for Colon Cancer, (CIRCULATE-NORTH AMERICA)
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT05174169
Protocol IDs
Treatment Sites (5)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
Piedmont Columbus Regional
Columbus
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
748.
Venetoclax and HMA Treatment of Older and Unfit Adults with FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Cancer Type
Leukemia
NCI ID
NCT06317649
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
749.
Venetoclax and Tocilizumab for the treatment of Patients with Relapsed or Refractory t(11;14) Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT05391750
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
750.
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT05183035
Protocol IDs
ITCC-101/APAL2020D
NCI-2022-07200
2021-003212-11
751.
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
Cancer Type
Hematopoietic Malignancies, Unknown Primary
NCI ID
NCT04847453
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
752.
Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT04590664
Protocol IDs
WINSHIP5070-20
NCI-2020-05187
753.
VGX-3100 and Electroporation in Treating Patients with HIV-Positive High-Grade Anal Lesions
Cancer Type
Anal Cancer, Unknown Primary
NCI ID
NCT03603808
Protocol IDs
AMC-103
AMC-103
NCI-2017-01740
754.
Vidutolimod (CMP-001) in Combination with Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT05445609
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
755.
Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL
Cancer Type
Leukemia
NCI ID
NCT02879643
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853
756.
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT02523014
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
757.
VitD3 Supplementation in Patients With Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT05846880
Protocol IDs
GCC-22-044
758.
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)
Cancer Type
Melanoma
NCI ID
NCT06264180
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
759.
Vorinostat in Preventing Graft Versus Host Disease in Children, Adolescents, and Young Adults Undergoing Blood and Bone Marrow Transplant
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma
NCI ID
NCT03842696
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
760.
Vudalimab in Combination with Standard of Care Treatment in Patients with Metastatic Castration Sensitive Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT05733351
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
761.
Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents with Cancer
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT03223753
Protocol IDs
ALTE1631
ALTE1631
COG-ALTE1631
NCI-2017-01219
762.
WP1066 for the Treatment of Recurrent or Refractory and Progressive Malignant Brain Tumors
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT04334863
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta
Atlanta
Howard M. Katzenstein, MD
404-785-0853